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Abstract 
 
Tamara Kay Nun:  Characterization of the latent K15 protein of Kaposi’s sarcoma-
associated herpesvirus and identification of compounds that disrupt viral latency 
(Under the direction of Blossom A. Damania, PhD) 
 
The Kaposi’s sarcoma-associated herpesvirus (KSHV) persists in a latent state in the 
healthy host without apparent disease.  However, in circumstances of diminished immune 
responsiveness, latent KSHV infection has been linked to three neoplastic diseases, 
including Kaposi’s sarcoma, primary effusion lymphoma and multicentric Castleman’s 
disease.  Cytokines, chemokines and growth factors play important roles in all three KSHV-
associated malignancies, stimulating tumor cell proliferation and neovascularization.  The 
restricted expression of viral proteins during latency minimizes the risk of immune 
recognition and also limits the number of potential therapeutic targets.  Currently, no drugs 
successfully target KSHV latency.  Thus there is no cure.  One potential therapeutic target is 
the latent membrane protein K15.  Multiple K15 isoforms result from alternative splicing of 
the K15 message.  However, all K15 isoforms are membrane-bound and share a long 
cytoplasmic tail with several conserved signaling motifs.  Given its location and potential 
signaling capacities, we investigated the function of the K15 protein in B lymphocytes.  We 
show that K15 expression alters the cytokine milieu.  K15 induces interleukin-6 (IL-6) 
expression by activation of AP-1 transcription factors.  IL-6 secretion is increased by K15 
alone or in the context of viral infection.  The viral IL-6 homolog is also induced by K15, 
stressing the important role of IL-6 cytokine signaling in viral pathogenesis.  Paradoxically, 
K15 also activates the STAT1 protein, normally shown to be active in the interferon 
response.  Our studies suggest that K15 signaling may enhance cell survival and promote 
viral latency.  Therefore, K15 might be a promising target for new pharmaceuticals.  In order
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 to screen samples for activity against latent viral infection, we developed a fluorescence-
based screening assay that we used to identify antiviral agents without bias to mechanism.  
Of 81 plant extracts screened, we found two potential hits that were relatively non-toxic to 
uninfected cells, highly toxic to naturally infected cells, and that exhibited selective viral 
inhibition in a latent model of infection.  These extracts may achieve their antiviral effects by 
disrupting the latency associated nuclear antigen (LANA) which tethers the viral episome to 
the host cell chromosome, ensuring the latent virus is not lost from the dividing cell 
population.   
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Kaposi’s Sarcoma 
In 1872 the Vienna-trained physician Moritz Kaposi published the first report of the 
lesions that would later bear his name(109).  Kaposi described five cases of aggressive 
idiopathic sarcomas arising on the hands and feet of middle-aged men in Austria.  The 
lesions ranged in size from a few millimeters to large coalescing plaques.  They were highly 
pigmented and hemorrhagic and were lethal in all cases.  In at least one case, multiple 
metastatic tumors in the esophagus, stomach and liver were found upon autopsy.  This 
cancer described more than 100 years ago is now known as Kaposi’s sarcoma (KS).   
Histologically, KS lesions are characterized by masses of spindle cells of endothelial 
origin (38, 62, 92, 96, 150).  Hyaline bodies may be found within the spindle cells and 
interspersed among the cells are vascular structures and spaces filled with red blood cells 
and pigmented hemosiderin (159).   Infiltrating inflammatory cells are also present.  An 
infectious etiological agent was long suspected, and viral particles and inclusion bodies in 
tumor sections were noted as early as 1972 (89, 216).  However, it was not until 1994 that 
Drs. Chang and Moore isolated unique viral DNA sequences from KS lesions using 
representational difference analysis (50).  Thus, the Kaposi’s sarcoma-associated 
herpesvirus (KSHV), also known as human herpesvirus-8, was identified as the etiological 
agent of KS.   
Four distinct epidemiological subtypes of KS have been described:  classic KS, 
epidemic (or AIDS-related) KS, iatrogenic (or post-transplant) KS, and endemic KS.  
Common among the four types of KS is the presence of KSHV DNA sequences in the KS 
lesions (37, 102).  However, the existence of multiple epidemiological subtypes of KS 
highlights the importance of environmental and/or host-specific co-factors in viral 
pathogenesis and oncogenesis.   
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Classic KS occurs primarily in aging Caucasian men of eastern European or 
Mediterranean descent, as described by Kaposi in 1872 (109).  The incidence of classic KS 
in Italy is two- to three-fold higher than in the U.S. and ten-fold higher than in the United 
Kingdom (86), with the highest incidence rate of 2.49 per 100,000 per year reported in 
southern Italy between 1998-2002 (16).  Classic KS may follow an indolent course with 
spontaneous regressions reported in some cases (206).  In cases with few cutaneous 
lesions, classic KS may be treated by excision or localized radiotherapy with great success 
(40, 214).  In cases with multiple lesions that may be difficult to treat with conventional 
therapies, targeting the mTOR pathway with sirolimus (rapamycin) has also been successful 
(97, 141). 
An outbreak of KS in San Francisco in 1981 signified the advent of a new 
epidemiological subtype of KS (149).  Epidemic KS describes KS that arises in HIV-positive 
populations.  Initially, epidemic KS was more common in men who have sex with men, but 
was also noted in IV drug users, Haitian natives and hemophiliacs (105).  Along with 
Pneumocystis carinii pneumonia, KS was one of the first AIDS-defining illnesses (105), 
occurring approximately 100 times more frequently in AIDS patients than in the general 
population (1).  Although still more common among men, as HIV continues to be spread by 
heterosexual contact and IV drug use, the incidence of epidemic KS among women 
continues to increase, as well, and may follow a more aggressive course (56, 154).  Highly 
active antiretroviral therapy (HAART) for HIV infection has reduced the incidence of 
epidemic KS, and immune reconstitution following HAART is associated with regression of 
epidemic KS (2, 46, 72, 73, 157, 212). However KS is still the leading neoplasm seen in 
HIV-infected individuals today (44).  HAART is the mainstay of treatment for epidemic KS, 
but localized treatment, conventional chemotherapeutics and immunomodulators are also 
considered (69). 
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Iatrogenic KS is a form of KS found in patients receiving immunosuppressive 
chemotherapy to prevent transplant rejection (168).  Incidence of iatrogenic KS is relatively 
low in post-transplant patients in the U.S. as compared to Europe and Saudi Arabia (77, 
140, 213).   Regression often follows cessation of the immunosuppressive regimen (26, 140, 
213, 225).  Sirolimus has also been shown to cause regression of post-transplant KS, while 
maintaining immunosuppression (114, 145, 175, 235).  
Prior to the HIV epidemic, KS was already endemic in some regions of Africa ((54) 
and reviewed in (104)).  Endemic KS occurs predominantly in young African males, although 
females are also affected (196).  The male to female incidence ratio increases with age.  
Usually uncommon in children, KS occurs with higher frequency in African children (60) .  It 
typically follows a very aggressive course, often involving lymph nodes (196).  Since the 
niveau of HIV, the incidence of KS has increased in Africa in both children and adults, and 
the gender disparities are equalizing (reviewed in (138)).  Additionally, the geographical 
distribution has widened to include regions of Africa where few cases have been reported 
previously (reviewed in (64)).  In addition to radiation and chemotherapy, recombinant 
interferon alpha has shown promise in treating cutaneous KS and stabilizing visceral tumors 
with symptomatic relief (184). 
Other KSHV-associated diseases 
Even before the discovery of KSHV as the etiological agent of KS, case reports were 
building an association between the lymphoproliferative disorder multicentric Castleman’s 
disease (previously named multicentric giant lymph node hyperplasia) and KS (51, 63, 70, 
98, 112, 113, 118, 185).  A common causative agent was suspected (185).  Shortly after the 
discovery of KSHV sequences in KS tissue, KSHV DNA was also isolated from multicentric 
Castleman’s disease (200).  In a large study to examine the prevalence of KSHV infection in 
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AIDS-related lymphomas, KSHV was also strongly associated with primary effusion 
lymphoma, previously named body cavity-based lymphoma (47).  Although a definitive role 
for KSHV has not yet been established, KSHV has been implicated in the pathogenesis of a 
number of other diseases, including multiple myeloma, primary pulmonary hypertension, 
and atypical Type II diabetes mellitus.  KSHV has been hypothesized to play a supportive 
role in multiple myeloma (36, 84, 181, 186).  However, an increased prevalence of KSHV 
DNA or seroprevalence in multiple myeloma patients has been refuted in many subsequent 
studies (57, 136, 161, 163, 169, 188, 211, 223).  In one study, KSHV infection was 
demonstrated in plexiform lesions and the surrounding tissue of primary pulmonary 
hypertension (PPH) (55), but the role of KSHV in PPH disease pathogenesis has been 
called into question (22, 59, 110, 124, 155).  Most recently, in a study of atypical type II 
diabetes mellitus patients of African origin, antibodies directed against latent and lytic 
antigens of KSHV were demonstrated in 88% of patients prone to ketosis versus 15% of 
patients not prone to ketosis (197).  KSHV DNA was also amplified from peripheral blood 
mononuclear cells in atypical ketosis-prone patients with increased frequency (197).  This 
preliminary evidence will undoubtedly spur future studies.  
Multicentric Castleman’s Disease 
 Clinically, Castleman’s disease presents as a polyclonal lymphocytic hyperplasia 
involving multiple lymphoid organs and cytokine dysregulation (201).  In particular, 
interleukin-6 (IL-6) levels are highly associated with disease progression and outcome (230).  
Three histological types of Castleman’s disease have been described: hyaline-vascular, 
plasma cell type, or mixed cell type.  Hyaline-vascular Castleman’s disease typically 
presents as a single mediastinal mass amenable to surgical excision with good outcomes 
(45).  The more aggressive plasma and mixed-cell types account for 10%-40% of localized 
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Castleman’s disease diagnoses and nearly all multicentric disease cases (99, 111).  
Multicentric Castleman’s disease is a multifocal neoplasm associated with peripheral 
lymphadenopathy, hepatosplenomegaly, and constitutional symptoms (82).  Multicentric 
Castleman’s disease is a corollary of the POEMS syndrome (polyneuropathy, 
organomegaly, endocrinopathy, monoclonal gammopathy, skin abnormalities) (88, 134, 147, 
153, 199).    
KSHV DNA sequences have been isolated from the plasmablastic variant of 
multicentric Castleman’s disease (200).  A strong association between HIV and KSHV 
positivity was established, although KSHV has also been detected in cases of HIV-negative 
MCD (49, 87, 160, 200).  Given that KSHV infection can be detected in only a subset of cells 
in MCD lesions, the role of the virus is likely co-stimulatory.  KSHV may contribute to 
cytokine dysregulation that is central to MCD by stimulating overexpression of cellular IL-6 
and by expression of the virus-encoded IL-6 homologue (vIL-6) (160).  Some patients have 
received benefit from antiviral and/or chemotherapeutic treatment strategies, but MCD has a 
poor prognosis and patients tend to suffer multiple relapses (25, 53, 139, 185, 191, 205).    
Primary Effusion Lymphoma 
 Primary effusion lymphoma (PEL) may occur in peritoneal, pericardial or pleural 
spaces, hence it was first called body cavity-based lymphoma (47, 94).  A sold mass may be 
undetectable.  Whereas the KSHV-infected endothelial cell represents the primary cell type 
that drives neoplastic growth in Kaposi’s sarcoma, the malignant cells in PEL are KSHV-
infected B lymphocytes.  Many B cell-specific surface markers are absent in PEL (151).  
However, gene rearrangement and surface marker studies have determined the 
lymphocytes are monoclonal and composed of post-germinal center B cells (76, 83, 137).  
KSHV sequences have been identified in >99% of AIDS-related PEL and have also been 
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isolated from PEL in HIV-negative hosts (15, 47, 152).  While PEL are invariably KSHV-
positive, co-infection with the closely related Epstein-Barr virus (EBV) is not uncommon (47, 
115).   
 Primary effusion lymphoma is more prevalent in HIV-positive patients and is 
associated with poor prognosis (15).  PEL is often refractory to treatment and relegated to 
supportive care.  Patients succumb to the disease within months.  In a study of HIV-
associated PEL, the 1-year overall survival rate was just 39% with the mean survival just 6.2 
months (32). 
Success and failure: current treatment strategies for KSHV-related malignancies 
 Patients presenting to clinic with Kaposi’s sarcoma, primary effusion lymphoma, or 
multicentric Castleman’s disease are treated with regimens similar to any other cancer 
patient.  Surgical excision, radiation and chemotherapeutic regimens including paclitaxel, 
doxorubicin, and duanorubicin are considered first-line of therapy for MCD, PEL and KS 
(68), as well as for many other non-virus-associated cancers.  These strategies are 
associated with severe toxicities, since they target all dividing cells and give no regard to the 
viral etiology of the tumors.  The incidence of KS has dramatically declined in regions where 
highly active antiretroviral therapy (HAART) has been available to treat concomitant HIV 
infection and boost the immune system (71, 75).  The realization that therapeutic benefit can 
be achieved by targeting the virus or the immune response has likely contributed to the 
recent push to develop targeted therapies more tailored to the pathogenesis of KSHV.   
Recently, immune modulators and antiviral drugs have come into fashion.  Interferon 
alpha has become a mainstay of treatment for MCD and has also benefited KS and PEL 
patients (12, 100, 116, 117, 158, 215).  However, like classic chemotherapy, interferon is 
associated with severe dose-limiting toxicities such as neutropenia and failed to eliminate 
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the latent reservoir (116).  Stochastic reports of therapeutic benefit from other targeted 
drugs such as rapamycin and antibodies directed against IL-6, for instance, sprinkle the 
literature, but very few randomized trials have been conducted to determine efficacy or to 
assist physicians in determining which patients will likely benefit.   
Classic anti-herpetic drugs such as ganciclovir, cidofavir and foscarnet have been 
successful in preventing KSHV-associated malignancies (91, 144), but success has been 
limited using these nucleotide analogs to treat existing disease (23, 130).  The major 
impediment to treatment with nucleotide analogs is that they are only effective at blocking 
lytic replication, whereas the majority of cells in KSHV-associated neoplasms are latently 
infected.  Somewhat better outcomes are achieved with these anti-herpes drugs in MCD, 
since MCD supports lytic replication.  However, it is important to note that treatment with 
these anti-herpes drugs does not eradicate the virus (103).  Drugs that target latent viral 
infection may prove more efficacious and tolerable and will be discussed in more detail in 
chapter 4. 
Kaposi’s sarcoma-associated herpesvirus classification 
 The unique viral DNA sequences identified by Drs. Chang and Moore in 1994 
resembled sequences of the tegument and capsid genes of another herpesvirus, the 
Epstein-Barr virus (50).  Indeed, based on sequence homology, host-specificity, viral 
pathogenesis and cell tropism, the Kaposi’s sarcoma associated herpesvirus, also known as 
human herpesvirus-8, became the newest member of a large family of human 
herpesviruses.  The Herpesviridae family is divided into three subfamilies.  Human 
pathogens of the Alphaherpesvirinae include Herpes Simplex viruses 1 and 2 (HSV-1 and -
2), as well as the Varicella-Zoster virus (VZV) (166).  The Alphaherpesvirinae establish 
latency in the dorsal root ganglia.  Spontaneous lytic reactivation is associated with oral or 
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genital herpetic lesions (HSV-1 and HSV-2) or in a dermatomal pattern on the skin or 
mucosae (VZV).  The Betaherpesvirinae, which include human cytomegalovirus (HCMV) 
and human herpesviruses -6 and -7 (HHV-6 and -7), cause symptomatic disease in a select 
group of susceptible hosts (166).  HCMV infection may result in graft rejection in 
iatrogenically immunosuppressed post-transplant patients (131) and is associated with 
congenital abnormalities when in utero transmission occurs (19).  HHV-6 and HHV-7 cause 
the childhood disease of roseola (101, 210).  The Gammaherpesvirinae are a collection of 
lymphotropic viruses with oncogenic potential.  Both KSHV and the closely related virus, 
EBV, are members of the gamma herpesvirus subfamily (166).  KSHV has been linked to 
the aforementioned B lymphocyte and vascular endothelial cell cancers.  EBV is associated 
with B-lymphocytic cell neoplasms as well as epithelial cell cancers.   
The Kaposi’s sarcoma-associated herpesvirus 
Like all herpesviruses, KSHV can establish a lifelong persistent infection in an 
otherwise healthy host.  The mode of transmission is still under debate with theories ranging 
from vertical transmission to horizontal transmission through sexual, salivary exchange, 
transfusion or transplantation routes (171).  Seroprevalence is highest in endemic regions.  
Despite low seroprevalence in the U.S., KSHV DNA and viral particles have been detected 
in oral mucosal cells of otherwise healthy hosts (74, 221) indicating that detection of KSHV-
specific antibodies may not be a sensitive measure of virus exposure. 
Characteristic of the Herpesviridae family, the KSHV is a large double-stranded DNA 
virus with two replication programs.   The 140-150 kb unique coding region is flanked by 
long terminal repeat regions adding from 20-25 kb of 801 bp repeat sequences (121, 179).  
The genome encodes more than 85 open reading frames (ORFs) and at least a dozen 
microRNAs.  Alignment of the sequences of multiple strains of KSHV indicates that the 
 10 
 
regions immediately adjacent to the terminal repeats contain the most variability (156, 174).  
Sequence analysis in these gene regions, which encode two viral membrane proteins, has 
been used to further define KSHV subgroups.  The linear viral genome is packaged in a 
proteinaceous capsid within the nucleosome, acquires the tegument, and is enveloped in a 
lipid membrane upon viral egress (166). 
The viral life cycle 
 KSHV infection is initiated when viral envelope proteins couple with receptors on the 
cell surface.  The KSHV envelope glycoproteins K8.1 and gB interact with heparan sulfate in 
the extracellular matrix (4, 6, 217) and may attract viral particles into the close proximity of 
the host cell, where the virus is more likely to bind cell surface receptors.  Glycoprotein gB 
coprecipitates with integrin α3β1, suggesting a role for this integrin in viral attachment (5).  
Engagement of the cystine:glutamate transporter protein xCT on the surface of the host cell 
is proposed to stimulate membrane fusion and viral entry (108).  After trafficking to the 
nucleus, the linear viral genome is released from the nucleocapsid and is transported into 
the nucleus.  At this point, the virus may instigate a highly ordered lytic replication program, 
with the goal of new progeny virion production and release.   In the majority of cells, 
however, the viral genome will circularize via its flanking terminal repeat regions and will 
persist in a latent state for the life of the host cell.  After establishing latency, the virus may 
also be recruited to produce new viral particles via lytic reactivation. 
Lytic Replication  
 During lytic replication, the complete repertoire of viral genes is expressed in a highly 
regulated cascading fashion (189, 209).  The immediate early (IE) genes are the first 
transcribed during lytic replication.  The IE genes include ORF50 which encodes the 
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replication and transcription activator (RTA) protein.  RTA acts as a transcription factor, 
initiating transcription from the promoters of the next wave of viral early (E) genes as well as 
some late (L) genes.  RTA targets the promoters of polyadenylated nuclear RNA, vIL-6, 
ORF6 (single-stranded DNA binding protein), ORF59 (DNA polymerase-associated 
processivity factor), thymidine kinase, and viral G-protein coupled-receptor among others 
(reviewed in (65)).  Early genes typically include genes that are required for viral DNA 
replication.  KSHV viral DNA replication is initiated at two lytic origins of replication (oriLyt) 
(18).  Core replication proteins (including the ssDNA binding protein, DNA polymerase, 
primase-associated factor, helicase, primase, and polymerase processivity factor), RTA and 
K-bZIP assemble as a complex at the oriLyt to initiate viral genome replication via a rolling 
circle mechanism (17).  Following viral genome replication, the final or late (L) wave of 
genes is transcribed.   Late genes encode structural proteins that form the capsid, as well as 
tegument proteins and membrane glycoproteins.  The nucleocapsids are assembled at the 
nucleus and the mature virions acquire an envelope from subcellular membranes as the 
particles exit the cell.    
In addition to the genes directly involved in and required for viral genome replication 
and packaging, viral proteins are also expressed during the IE, E and L phases that perform 
auxiliary roles, enhancing the process by diverting signal transduction pathways and the 
host cellular machinery and subverting the immune response.  Some auxiliary viral genes 
encode proteins with cellular homologues that may enhance proliferation (vIL-6 protein), 
dysregulate cellular signaling pathways (viral G-protein coupled receptor or vGPCR), 
modulate the host immune response (viral interferon regulatory factors or vIRFs and 
macrophage inhibitory peptides or vMIPs), or prevent apoptosis (viral bcl-2-like protein or 
vBCL-2) (43, 146, 156, 190).  Other viral genes encode proteins with structural and/or 
functional homology to proteins encoded by other herpesviruses.  For instance, the two 
most extreme viral ORFs K1 and K15 encode viral membrane proteins, which resemble the 
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latent membrane proteins (LMPs) of the EBV both structurally and functionally.  Like LMP1, 
ectopic expression of K1 in Rat-1 fibroblasts leads to a transformed phenotype (126).   
Additionally K1 expression deregulates B cell receptor signaling (122, 125) and induces 
invasion and angiogenic factors in epithelial and endothelial cells (219), similar to LMP1.  
The viral membrane protein K15 is the subject of this dissertation and will be discussed in 
more detail.  Still other viral genes have no function ascribed them, yet.     
Latency 
 More commonly, KSHV does not proceed to productive infection but establishes 
latency in an infected lymphocyte or endothelial cell.  In the three KSHV-associated 
malignancies, the majority of infected cells are in fact latently infected, with only a small 
percentage of cells undergoing spontaneous lytic reactivation at any given time (estimated 
to be 2-5% of cells in PEL but up to 25% in MCD) (14, 29, 143).  During latency, a small 
cadre of viral genes is expressed.  This contingent of viral gene products is thought to be 
absolutely essential for maintenance of the circularized viral genome, or episome, and also 
to encode viral oncogenes.  Given the large size of the KSHV genome, limited expression of 
viral genes during latency is a highly efficient survival mechanism.  Transcription of only a 
handful of genes is certainly less taxing than initiating the full transcriptional program and 
allows the virus to be maintained by the host cell throughout its lifetime without exhausting 
cellular resources.  Furthermore, restricted gene expression may ensure that the virus 
persists without triggering host immune responses.   
The most studied of the latent viral proteins is the latency-associated nuclear antigen 
(LANA).  LANA tethers the viral episome to the host chromosome via the terminal repeats 
(58, 85), thus ensuring that the viral genome is replicated along with the host chromosome 
in dividing cells and is equally segregated to each daughter cell upon cell division (20).  
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LANA is a fairly promiscuous protein with interactions demonstrated between LANA and 
various cellular proteins, including p53, pRb, GSK3β, and histone subunits, among others 
(21, 79, 80, 127, 173, 176).  LANA, with its many functions, is pivotal in maintenance of the 
viral genome and in the oncogenic process.  LANA is transcribed along with viral cyclin 
(vCyclin) and viral FLICE inhibitory protein (vFLIP), which causes cell cycle perturbations 
and inhibits apoptosis, respectively.  The viral microRNAs are also encoded at the same 
locus (41, 165, 170, 187).  Deciphering the roles of the viral microRNAs is an area of 
research that is currently hotly pursued.  One of the viral microRNAs, miR-K12-11 has 
shown similarity in seed sequence to the cellular miR-155 as well as in target sequence 
prediction programs and genetic profiling assays (93, 195).  However, validation of target 
sequences remains a difficult process.  Finally, kaposin and K15 are also expressed during 
latency.  K15 is the focus of much of the work in this thesis and will be discussed in more 
detail in a later section. 
Lytic reactivation 
After the virus has established latency in the host cell, it may undergo lytic 
reactivation in response to cellular or environmental stimuli.  In culture, lytic reactivation is 
achieved by chemical induction with phorbol esters, which activate protein kinase C signal 
transduction pathways, or with N-butyrate, which is a histone deacetylase (143, 180).  
Furthermore, overexpression of the lytic switch protein RTA is also sufficient to induce lytic 
reactivation in tissue culture (132, 208).  Importantly, no treatment is 100% effective at 
inducing lytic replication.  Chemical induction or expression of RTA overcomes repression of 
lytic replication in approximately 30% of PEL cells in culture.  Hence, modeling lytic 
replication of KSHV in tissue culture is often confounded by a high background of cells 
remaining in a latent state.  Hypoxia and changes in cytokine secretion (especially interferon 
 14 
 
and interleukin-6) into the microenvironment have also been reported to cause spontaneous 
lytic reactivation of some infected cells in culture (3, 61, 198).  In vivo stimuli are unknown, 
but hypoxia and cytokine secretion are valid hypotheses.    Environmental stimuli have also 
been reported including volcanic soils, mineral deposits in the soil, and herbal remedies that 
might contain natural activators of lytic replication (194, 224, 233). 
The viral K15 protein 
The K15 ORF is located at the far right end of the genome, immediately adjacent to 
the right terminal repeat region.  Given its placement next to the terminal repeat, K15 
sequences are highly variable between viral isolates, as compared to centrally located gene 
sequences.  Two divergent alleles have been described—the P or predominant allele and 
the M or minor allele.  Overall, the two alleles share approximately 33% sequence identity 
(174).  The K15-M allele is thought to represent an ancestral allele that resulted from 
recombination with a closely related rhadinovirus and is more common in A and B strains of 
KSHV (119, 174).  Of particular note, multiple putative signal transduction domains have 
been described that are conserved between the two K15 alleles, highlighting the importance 
of these signaling sequences to the function of K15.  The signaling functions of the K15-P 
allele are investigated in Aim 1 of this thesis.    
The viral K15 protein has been described as a latent protein and initially was named 
the latency-associated membrane protein or LAMP (90).  Viral K15 transcripts have been 
isolated from latently infected cells and protein expression has been detected in uninduced 
PEL cell lines (52, 90, 193).  We, and others, have shown that K15 expression increases 
upon induction of lytic replication with RTA overexpression and/or chemical induction (35, 
52, 90, 227).  Thus, K15 is not a latent gene in the strictest sense, since it is highly induced 
during the lytic phase of the viral lifecycle.  Given that its expression has been detected in 
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Figure 1.1  The K15 protein contains multiple transmembrane domains and conserved 
signaling domains in its cytoplasmic tail.  The amino acid sequence of K15 is depicted in the 
putative structure of the full length K15 protein.  The full length K15 protein encodes 12 
membrane spanning domains.  Smaller isoforms (designated by bars in the amino acid 
sequence) encode variable numbers of transmembrane domains but share multiple highly 
conserved signaling domains in the common cytoplasmic tail, including SH2 and SH3 (src-
homology) binding sites, a TRAF (tumor necrosis factor receptor-associated factor) binding site, 
and two putative WW domains.  
both PEL and MCD lesions by immunohistochemistry, K15 likely plays an important function 
in latency as well as during lytic replication.   
The K15 gene is transcribed from right to left and encodes multiple alternatively 
spliced transcripts.  The full length K15 P-transcript contains eight exons and encodes a 
45kDa protein with 12 predicted transmembrane domains (52, 90, 156).  The smaller K15 
isoforms are transcribed with an alternative first exon and share a variable number of exons 
with the full length isoform (52, 90, 156).  All K15-P isoforms contain a long cytoplasmic tail 
with conserved constitutively phosphorylated tyrosine residues that constitute binding sites 
for proteins containing src-homology (SH)-2 domains, SH3 domains, and tumor necrosis 
factor receptor-associated factors (TRAFs) (Figure 1.1).   
 16 
 
Multiple signaling pathways have been shown to be activated by the K15 protein.  
For instance, the YEEVL and YASIL motifs represent putative SH2-binding sites in the C-
terminal cytoplasmic tail that activate multiple MAPK pathways, while interactions with 
TRAFs lead to induction of the NF-κB signal transduction pathway (34, 90).  The SH3-
binding site has been shown to bind the SH3 domain of the intersectin-2 protein, which is 
involved in the regulation of endocytosis (128).  Like K15-P, the K15-M proteins are derived 
from multiply spliced transcripts and contain highly conserved putative SH2 and SH3 
domains in the cytoplasmic tail.  The phosphotyrosine of the conserved YEEV motif is also 
required for activation of the MEK/Erk2 MAPK and NF-κB signal transduction pathways by 
K15-M, but not for JNK activation (218).  Target genes induced by K15-M are similar to 
those of K15-P and include inflammatory cytokines such as interleukin-6 and -8 (218).   
K15 proteins are incorporated into lipid rafts (34).  Various groups have shown K15 
localized to multiple cellular membranes, including the plasma membrane (34, 52, 90), 
perinuclear or endoplasmic reticular membranes (52, 90, 193, 218), and potentially even 
mitochondrial membranes where it appears to bind the anti-apoptotic protein Hax-1 (193).    
Expression of K15-P in epithelial cells induced the expression of multiple cytokines, 
including interleukin (IL)-1α/β, IL-6, IL-8, CCL2, CCL20 and CXCL3 (35).  These cytokines 
may play a role in cell survival and proliferation and may also play immunomodulatory roles 
that help the virus escape detection by circulating antigen presenting cells. 
KSHV and the immune response 
The host organism mounts a multi-faceted defense strategy to identify and eliminate 
detrimental pathogens like KSHV.  The consequences may be dire for the invading 
pathogen.  Thus, in a fight for survival, evasion tactics become necessary.  In the case of 
herpesviruses, induction of the innate immune response may select for survival of cells in 
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which the virus has gone latent with a restricted antigen profile.  It may also exert 
evolutionary pressure on the virus to either actively block or subvert the innate immune 
response to its own advantage.  For example, activation of innate the immune response 
may result in chemokine induction that recruits monocytes, dendritic cells and lymphocytes 
to the site of initial infection.  These infiltrating cells may themselves be susceptible to viral 
infection and may serve as an easy conduit for viral spread.   
Primary defenses against invading pathogens in the host incorporate multiple 
mechanisms for recognition and elimination of the offender.  Pattern recognition receptors, 
such as the toll-like receptors (TLRs), and retinoic acid inducible gene-I (RIG-I) alert the cell 
to the presence of viral nucleic acid or protein and initiate the antiviral response.  KSHV 
activates the toll-like receptor 3 (TLR3) during primary infection of monocyte cells, resulting 
in upregulation of TLR3 via a positive feedback loop and upregulation of TLR3-induced 
cytokines including CXCL10 and type I interferon (222).  In addition to cellular pattern 
recognition molecules, differences in membrane structure of invading pathogens may trigger 
the complement cascade (234).  Deposition of complement culminates in hydrolysis of the 
invading pathogen or infected cell through pores formed by the membrane attack complex.  
The complement control protein (KCP) of KSHV actively inhibits the complement cascade 
(202). 
Following the innate immune response, a healthy host normally develops adaptive 
immunity to include cell-mediated and humoral immunity to invading pathogens.  It is 
believed that a T-cell mediated immune response keeps KSHV in check during the lifetime 
of the asymptomatic host harboring a latent virus in his B lymphocytes.    Cytotoxic T 
lymphocyte (CTL) epitopes have been identified in both latent (33, 142, 226) and lytic (142, 
204, 220, 226) viral gene products.  Memory CTL responses have been detected in 
otherwise healthy individuals (142).  Failure of cell-mediated immunity is met with an 
increased prevalence of KSHV-associated malignancies, both in the setting of 
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immunosuppressive therapies administered to prevent graft rejection in post-transplant 
patients and in the setting of the Acquired Immunodeficiency Syndrome (AIDS) when CD4+ 
T cell counts drop to <200/ml (77, 115, 167). 
Secretion of soluble factors represents an important branch of the cellular 
communication network.  Cytokines and chemokines often signal the presence of invading 
pathogens and represent a request for professional assistance in elimination of the threat, 
either by innate immune cells or by the more experienced B- and T-lymphocyte cells.  As 
mentioned previously, KSHV encodes multiple homologues of cellular cytokines and 
chemokines, such as vIL-6, vIRFs, and vMIPs (156).  Regulation of the viral homologues is 
skewed in favor of the virus.  For example, the vIRFs impede the cellular antiviral response 
by suppressing interferon signaling and transcriptional activity (39, 81, 129), while the vIL-6 
supports growth and prevents apoptosis in IL-6 dependent cell lines (146).  In addition to 
viral homologues, the virus also encodes proteins that increase expression of stimulatory 
cytokines or anti-apoptotic cytokines, which are central to pathogenesis of the KSHV-
associated malignancies.  For instance, the K1 protein of KSHV induces expression of the 
vascular endothelial growth factor (VEGF) (219), which has been shown to be important for 
the pathogenesis of the highly vascularized KS lesions.  Cellular IL-6 and IL-10 levels are 
high in PEL cells (107).  De novo viral infection and ectopic expression of LANA have been 
shown to cause increases in cellular IL-6 expression (11, 229).    
Infection model systems 
Since the discovery of KSHV in 1994, attempts to develop an efficient system for 
viral propagation in culture has been highly sought without much success.  Cell lines derived 
from KS tissue samples lose the virus in serial passage (8, 9).  However, multiple cell lines 
have been derived from PEL cells following adaptation to tissue culture (13, 31, 42, 48, 
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180).  These PEL cell lines maintain a high copy number of viral genomes in culture (123).  
As expected, the majority of cells are latently infected, with 2-5% of cells undergoing 
spontaneous lytic replication (180).  Therefore, PEL cell lines provide relatively efficient 
models for studying the role of viral proteins during latency.  However, only a few viral genes 
are naturally expressed during viral latency (106, 164, 189), so the utility of the latently 
infected PEL cell system is pronounced in laboratories that study the functions of latent 
proteins.  Lytic reactivation can be induced as previously described (180), but the results of 
such experiments must be considered in light of the high background of cells remaining 
latent since only a subset of cells will proceed to lytic amplification of the virus.  Furthermore, 
this system fails to elucidate how KSHV transforms B lymphocytes, since transformation has 
already occurred prior to the establishment of the cell line for tissue culture.  Infection of 
primary B lymphocytes, epithelial, and endothelial cells has been achieved and has provided 
useful systems to study viral infection (10, 30, 120, 177).  The utility of these systems is 
limited, however, since they do not support sustained lytic replication or long-term viral 
genome maintenance.    
Systems for studying the role of viral proteins by reverse genetics have recently been 
employed.  Recombinant viruses have been constructed using a series of overlapping 
cosmids, in which one or more elements have been mutated or deleted.  In 2002, a bacterial 
artificial chromosome (BAC) was created containing the entire KSHV genome, a hygromycin 
expression cassette for mammalian selection, and a green fluorescent protein expression 
cassette for visual screening (231).  Mutants have been created by transposon-mediated 
mutagenesis or homologous recombination using this KSHV-BAC system (133, 231, 232).  
The KSHV-BAC system allows the viral DNA to be grown to high copy number in bacterial 
cells.  The BAC DNA can then be transfected into cells in culture, circumventing any entry 
blockades to viral infection.  Introduction of the KSHV-BAC into epithelial 293 cells achieves 
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a higher percentage of cells undergoing lytic reactivation upon chemical induction, as 
compared to PEL cell lines allowing more rigorous studies of lytic phase viral proteins. 
In vivo infection models are complicated by the restricted host range of KSHV but 
many new models have been developed to study KSHV biology and pathogenesis.  Long-
term KSHV-infected telomerase-immortalized human umbilical vein endothelial (TIVE) cells 
formed tumors in nude mice modeling KS (10).  Early studies modeled KSHV-associated 
malignancy formation by inoculating SCID mice introperitoneally or subcutaneously with 
PEL cells (31, 172).  Clinical hallmarks of this system include lymphomagenesis and ascites 
formation.  This system is labor and time intensive, requiring both a long latency period and 
a large number of cells in order to establish detectable tumors.  Injecting PEL cells with 
matrigel into mice has proven to hasten tumor development (203).  Reverse genetics are 
difficult in this system, but cells stably transfected with wild-type or recombinant KSHV-BACs 
could be employed in a similar manner to study the contribution of single genes on tumor 
formation (148).   
More recently SCID mice have been injected with KSHV virions to study de novo 
infection and tumor progression.  SCID mice engrafted with human skin developed KS-like 
lesions when virus particles were injected into the graft (78).  Persistent infection of 
humanized NOD/SCID mice following injection of purified KSHV virions revealed that KSHV 
targets lymphocyte and monocyte cell populations (162).  6% of KSHV-injected mice 
developed splenomegaly during this relatively short study, but tumor formation could not be 
confirmed.  Nonetheless, this system represents a unique and promising model to study de 
novo KSHV infection.  Long-term studies may prove the potential of this system to model 
KSHV-associated tumorigenesis, as well. 
Attempts to study KSHV pathogenesis in a more relevant non-human primate model 
have been hampered by the species specificity of KSHV.  SIV-infected or uninfected rhesus 
macaques permitted low levels of persistent KSHV infection, but did not seroconvert or 
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exhibit KSHV-related disease progression (178).  These findings suggest that KSHV 
infection may be abortive in rhesus macaques and therefore is not a good in vivo model for 
KSHV pathogenesis.  The closely related gammaherpesviruses rhesus monkey rhadinovirus 
(RRV) and retroperitoneal fibromatosis-associated herpesvirus (RFHV) may serve as in vivo 
models of KSHV biology and pathogenesis, since they are associated with similar diseases 
in their natural hosts.   
The organization of the genomes of RRV and KSHV are markedly similar, with each 
ORF of RRV represented in KSHV (7, 192).  For most genes, some degree of sequence 
homology is observed between the viruses.  However, KSHV does contain some unique 
sequences that are not present in RRV.  An estimated 90% of captive rhesus macaques 
have antibodies directed against RRV antigens (24, 66).  Experimental infection studies 
revealed that RRV causes lymphadenopathy resembling MCD and implicated RRV may play 
a role in the generation of KS-like lesions in SIV-infected macaque s (135, 228).  The major 
advantage of using the RRV system is that the virus can be grown lytically to high titers in 
rhesus fibroblasts or can be used to model latency in other cell types, such as B 
lymphocytes (27, 67).  Thus, in vivo studies that require large amounts of virus are possible 
by growing large amounts of virus in vitro in the lytic RRV culture system.  Furthermore, for 
studying the contribution of individual genes to viral pathogenesis and oncogenesis, reverse 
genetic systems have been described which increase the utility of this system considerably 
(28, 67), especially given that the system allows the investigation of lytic as well as latent 
viral protein functions.        
RFHV was isolated from simian AIDS-associated KS-like retroperitoneal fibromatosis 
(RF) tissue samples harvested at necropsy from macaques during an epidemic in 
experimental primate colonies (183).  RFHV has not been detected in peripheral blood 
mononuclear cells of living RF-negative macaques.  Sequence analysis reveals that RFHV 
is very closely related to KSHV (182) and may be an ideal virus to study KSHV-related 
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diseases in a non-human primate model.  Additionally, more recent studies have identified 
other viruses that are closely related to both KSHV and RFHV (95, 207), presenting new 
options for the pursuit of a suitable animal model of infection. 
Project outline 
As discussed previously, KSHV is associated with multiple neoplastic diseases, 
including two B-cell malignancies and one of endothelial origin.  Although multiple treatment 
strategies have been tried and met with variable success, no strategy available today has 
the ability to cure the latent reservoir of infection with KSHV.  The only specific antiviral 
agents in wide use are nucleotide analogs that selectively target the viral thymidine kinase 
and block lytic DNA replication.  These antiviral agents have generally been more 
efficacious in MCD, where a higher percentage of infected cells are engaged in the lytic 
cycle, but the latently infected cells persist regardless.  Thus, the overarching theme of this 
dissertation is to elucidate potential mechanisms for disrupting KSHV latency.  Our 
approach is two-pronged.  Our first approach was to investigate the function of the relatively 
understudied latent viral membrane protein K15.  By understanding the role of K15 in viral 
infection, we may reveal new “druggable targets” or a means to swing the pendulum back in 
the favor of cell survival and out of the favor of viral proliferation and pathogenesis.  The 
second approach was to devise a method to screen potential antiviral agents (regardless of 
mechanism) for activity against latent viral infection. 
 
1) Characterization of signal transduction pathways activated by K15 in B lymphocytes 
Prior to this work, little was known about the function of K15 in B lymphocyte cells.   
An early report indicated that when fused to the extracellular domain of the CD8 molecule, 
K15’s cytoplasmic tail could inhibit B-cell receptor signaling as measured by calcium 
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mobilization experiments (52).  Other than that study, the function of K15 had only been 
investigated in epithelial or endothelial cell lines.  K15 expression has been detected in both 
B-cell malignancies (52, 90, 193).  Therefore, studying the function of K15 in B lymphocytes 
seemed highly relevant.  Given that the K15 protein localizes to membranes and its 
signaling functions have been demonstrated in epithelial and endothelial cell lines, we 
suspected that K15 might also activate signaling pathways in B lymphocyte cells and that 
the signals initiated by K15 may promote changes in the cytokine milieu that promote viral 
pathogenesis and/or oncogenesis.  Our suspicions instigated the studies undertaken in Aim 
1.  In addition to studying K15-mediated changes in cytokine expression, we also 
investigated the JAK-STAT pathway, a signaling pathway activated in response to multiple 
cytokines, including IL-6 and Oncostatin M.   
 
2) Characterization of K15 function in the KSHV viral life cycle. 
In addition to studying K15 function in overexpression experiments in B lymphocytes, 
we also used the KSHV-WT and KSHV-∆K15 bacterial artificial chromosomes to examine 
the function of K15 in the context of viral infection.  We examined K15-mediated changes in 
cytokine expression.  We studied cell growth and performed viral load assays in B 
lymphocytes harboring WT-KSHV or KSHV∆K15 genomes to determine the effect of K15 
expression on cellular proliferation and infection status. 
  
3) Development of an assay to screen antiviral drugs against KSHV 
In order to identify antiviral agents with activity against latent viral infection, we 
employed the KSHV-BJAB system to model latent viral infection of B lymphocytes.  A 
beneficial feature of this system was that cells harboring the virus expressed the green 
fluorescent protein, thus providing an easy method for screening the samples with 
sequential fluorescence measurements from the infected cultures. 
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Abstract 
Growth factors and cytokines play important roles in two B cell malignancies linked to 
Kaposi’s sarcoma-associated herpesvirus (KSHV).  IL-6, IL-10, and Oncostatin M are 
secreted in large amounts in primary effusion lymphoma.  IL-6 dysregulation and over-
production contribute to multicentric Castleman’s disease pathogenesis.  In addition, the 
virus encodes a viral IL-6 (vIL-6) homolog that is highly expressed and stimulates 
proliferation of infected cells.  We investigated the effect of the viral membrane protein K15, 
which has been detected in both B cell malignancies, on cytokine expression in B cells. 
Among other cytokines, in B lymphocytes K15 induced expression of Oncostatin M and IL-6, 
which bind their respective receptors in complex with gp130 to initiate JAK-STAT signaling.  
Given the well-defined role of IL-6 in KSHV-associated diseases, we probed the mechanism 
of K15-mediated IL-6 induction and the downstream JAK-STAT pathway.  Four K15 
isoforms induced cellular IL-6.  Reporter assays demonstrated that K15 signaling via the 
AP-1 pathway activates the cellular IL-6 promoter.  The viral IL-6 promoter is also activated 
by K15.  Additionally, we found that K15 expression leads to phosphorylation of the 
activating tyrosine residue of the signal transducer and activator of transcription 1.   
Introduction 
Although the absolute numbers of cancer deaths in HIV-positive patients has 
declined since the advent of the highly active antiretroviral therapy (HAART), Kaposi’s 
sarcoma (KS) is still the leading cancer in the HIV positive population (8).  KS caused 13% 
of all deaths of HIV-positive patients in the post-HAART era (17).  In 2000, KS was 
responsible for 27% of deaths due to AIDS-associated malignancies in France.  The 
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8, is 
the etiological agent of KS (11).  In addition to KS, KSHV has also been implicated in two B 
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cell malignancies— primary effusion lymphoma (PEL) (9), and the plasmablastic variant of 
multicentric Castleman’s disease (MCD) (75).  KSHV-associated malignancies are more 
common in post-transplant patients and patients with AIDS (9, 10, 47, 55, 75).  Currently 
there is no cure for viral infection. 
The majority of infected cells in all three KSHV-associated malignancies remain 
latent, with a small percentage of cells undergoing spontaneous lytic replication at any given 
time (91).  During latency only a few viral genes are expressed (35, 73, 78, 91), allowing the 
virus to escape immune surveillance and to persist without symptoms for the lifetime of an 
otherwise healthy host.  One gene expressed during latent infection in PEL and MCD 
encodes the viral K15 membrane protein (14, 29, 65, 74).   
Multiple K15 isoforms arise from alternatively spliced transcripts (14, 29, 65).  The 
full-length transcript contains eight exons and encodes a protein with a predicted molecular 
mass of 45-50 kDa and 12 membrane-spanning domains.  Three smaller K15 isoforms 
(Clones 1, 15 and 20) have a common alternatively spliced first exon, that is distinguished 
from the first exon of the full-length isoform (Clone 35), and share a variable number of 
exons with Clone 35 (Figure 2.1A).  Clones 1 and 35 share exons 2 through 7, Clones 20 
and 35 share exons 4 through 8, and Clones 15 and 35 share exons 5 through 8 (14).  
Thus, the isoforms encode a variable number of transmembrane domains, but they all 
maintain identical cytoplasmic tails that contain several conserved signaling motifs.   
SH2, SH3 and TRAF binding sites are present in the cytoplasmic tails of all K15 
isoforms (3, 41, 65, 88).  In epithelial cells, K15 activation of the Ras and JNK MAPK 
signaling pathways is dependent on Src-mediated phosphorylation of the tyrosine residue in 
the Y481EEV potential SH2 binding site.  K15 initiates NF-κB signaling through the TRAF 
binding site, which has been shown to recruit TRAFs 1, 2 and 3 (3).  Highlighting the 
importance of the SH3 binding sequence PPLP of K15, a recent study found an interaction 
between the PPLP residues and an SH3 domain of the Intersectin 2 protein, a cellular 
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regulator of endocytosis (41).  An interaction between K15 and the inhibitor of apoptosis 
Hax-1 suggests a potential anti-apoptotic role for K15 (74).   
Despite demonstrating the signaling capabilities of K15, few studies have 
investigated the consequences of K15 signaling.  Recently, K15 signaling has been shown 
to cause cytokine perturbations in epithelial cell cultures.  The expression of K15 in HeLa 
cells induced expression of IL-8, IL-6, CCL2, CCL20, IL1α/β, and CXCL3 (4).  In this 
chapter, we investigate the role of K15 in cytokine production and signaling in B lymphocyte 
cells.  Although K15 caused increases in multiple cytokines, we focused on IL-6 expression 
and JAK-STAT signaling, given the central role for this pathway in KS, PEL and MCD 
pathogenesis.  cDNA constructs of four previously described K15 isoforms and a genomic 
K15 construct exhibited increases in IL-6 transcription and protein expression.  We identified 
an AP-1 site in the IL-6 promoter that was required for activation by K15 and an NF-κB site 
that augmented activation.  Activation of NF-κB and AP-1 transcription factors in B 
lymphocyte cells required tyrosine phosphorylation of the Y481EEV motif in the cytoplasmic 
tail of K15.  This motif was also required for IL-6 promoter activity.  In addition, K15 
expression stimulated transcription from the viral IL-6 promoter and resulted in increased 
vIL-6 protein expression in BCP-1 cells.  Finally, K15 also activated the downstream signal 
transducer and activator of transcription 1 (STAT1) protein. 
Materials and Methods 
Cell Maintenance 
BJAB (KSHV-negative B cell lymphoma) cells (49) were maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL 
streptomycin.   KSHV-positive but EBV-negative primary effusion lymphoma BCP-1 cells 
(ATCC CRL-2294) were maintained in RPMI-1640 medium supplemented with 10% fetal 
 48 
 
bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin, 0.1% 2-mercaptoethanol, 
and sodium bicarbonate solution.  Growth medium and supplements were obtained from 
Cellgro. 
Expression of K15 cDNA and genomic constructs   
Flag epitope-tagged cDNA expression constructs of four K15 isoforms (Clones 1, 15, 20 and 
35)(14) were PCR amplified and cloned downstream of the SRα promoter in the pFJAE 
plasmid using BamHI and EcoRI restriction enzymes.  The Flag epitope-tagged genomic 
K15 construct was PCR amplified from viral DNA isolated from BCBL-1 cells.  The genomic 
K15 construct was inserted into the pFJAE expression plasmid using KpnI and EcoRV 
restriction enzymes.   6 x 106 BJAB cells were transfected with 5µg of K15 expression 
plasmid or the pFJAE parent plasmid using the B cell transfection kit from Amaxa and the 
nucleofection program T-16.  Following transfection cells were grown in complete growth 
medium for 48h, then lysed, subjected to SDS-PAGE and transferred to nitrocellulose 
membranes for detection of K15 proteins with an HRP-conjugated anti-ECS antibody 
(Bethyl).    
Cytokine Array 
BJAB cells were transfected as described.  48h post-transfection, cells were washed and 
serum starved for 24h.  Conditioned growth medium was collected from the cells and 
centrifuged to remove cellular debris, before incubation with two cytokine antibody arrays 
(Raybiotech).  A total of 84 cytokines are represented on two membranes VI and VII.  The 
membranes were blocked, and then incubated with conditioned medium from BJAB cells 
expressing K15 or a vector control.  Membranes were incubated with a primary antibody 
mixture, then an HRP-conjugated secondary antibody and finally with chemiluminescent 
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substrate.  Membranes were exposed to film and individual dot intensity was measured 
using the ImageJ software available through NIH. 
IL-6 ELISA 
BJAB cells were transfected as described.  48h post-transfection, cells were washed and 
serum starved for 24h.  Conditioned growth medium was collected from the cells and 
centrifuged to remove cellular debris.  In some experiments, medium was concentrated by 
centrifugation with a centricon-10 protein concentrator.  Secreted IL-6 was detected using a 
typical sandwich ELISA (eBioscience) as per manufacturer’s instructions.   
RT-PCR 
Following 24h serum starvation, RNA was isolated from BJAB cells expressing K15 or a 
vector control using an RNeasy (Qiagen) RNA isolation kit.  1µg RNA was reverse 
transcribed with the Reverse Transcription System (Promega).  PCR was performed with 
the following primer pairs:  β-actinF 5’- GGCATCGTGATGGACTCCG-3’ and β-actinR 5’- 
GCTGGAAGGTGGACAGCGA-3’, K15 SeqF2 5’-GCTGTGTTGATGACAAACATGCTGG-3’ 
and K15 SeqR2 5’- GACTTAATCCTGCAGCGGTGG-3’, or IL6F 5’-
GGTACATCCTCGACGGCATCTC-3’ and IL6R 5’-GTTGGGTCAGGGGTGGTTATTG-3’.  
PCR products were resolved by electrophoresis through 1-2% agarose gel and visualized 
with ethidium bromide staining. 
Human (hIL-6) promoter luciferase assays 
Human IL-6 promoter luciferase plasmids were obtained from the Belgian Co-ordinated 
Collections of Micro-organisms/ LMBP  Plasmid and DNA library collection (BCCM/LMBP) 
(Figure 2.5A)(84).  The full length promoter reporter plasmid p1168huIL6P-luc+ (or LMBP 
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4495) consists of 1168nt upstream of the IL-6 gene transcription initiation site driving 
expression of the luciferase reporter gene.  Promoter deletion mutants p50huIL6P-luc+ (or 
LMBP 4692), p110huIL6P-luc+ (or LMBP 4693) and p234huIL6P-luc+ (or LMBP 4694) 
contain 50, 110 and 225bp of the human IL-6 promoter.  Point mutants of an NF-κB 
responsive element (p1168hIL6mNFkB-luc+ or LMBP 4496) and AP-1 responsive elements 
(p1168hIL6m3AP1-luc+ or LMBP4492) were created in the context of the full length IL-6 
promoter.  
 
6 x106 BJAB cells were transfected with 5µg K15 expression construct, a K15 Y481F 
mutant, or pFJAE vector as a control plus 0.5µg of a human IL-6 promoter luciferase 
reporter plasmid using the B cell nucleofection kit (Amaxa) and the nucleofection program T-
16.  Cells were incubated for 48h in complete medium, then serum-starved for 24h.  
Luciferase activity was assessed in 50µl of lysate following addition of luciferase substrate 
(Promega) and normalized to total protein content in the sample.   
Measurement of NF-κB and AP-1 activity 
NF-κB activity was measured in BJAB cells transfected with 2-5µg of the genomic K15 
construct and 100ng of the NF-κB -luciferase reporter plasmid pNF-κB luciferase (Clontech).  
AP-1 activity was measured in BJAB cells transfected with 5µg of the genomic K15 
construct and 500ng of the TRE (TPA-responsive element)-luciferase reporter plasmid (kind 
gift of Dr. Al Baldwin).  In order to determine the effect of K15 signaling on transcription 
factor activation, 5µg of K15 Clone 35, K15 Y481F or a vector control were co-transfected 
with either 100ng of pNF-κB luciferase or 500ng of TRE-luciferase into BJAB cells.  Cells 
were grown in RPMI + 10% fetal bovine serum for 48h, then were washed and grown in 
serum-free medium for an additional 24h.  Cells were lysed in reporter lysis buffer 
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(Promega) and NF-κB -driven luciferase activity was measured in 50µl of lysate.  A Bradford 
assay was performed in tandem to determine the total protein concentration of each sample.  
Relative luciferase units were normalized to total protein content.   
pSTAT1 detection 
BJAB cells were transfected as described previously.  Lysates were subjected to 10% SDS-
PAGE, transferred to nitrocellulose membranes and immunoblotted with phospho-Tyr701 
STAT1-specific antibody, phospho-Ser727 STAT1-specific antibody, or total STAT-1 
specific antibody (Cell Signaling) to assess phosphorylation status of the downstream 
STAT1 molecule.   
vIL-6 promoter luciferase assays 
6 x106 BJAB cells were transfected with 5µg K15 expression construct or pFJAE vector as a 
control plus 0.5µg of a viral IL-6 promoter luciferase reporter plasmid using the human B cell 
nucleofection kit (Amaxa) and the nucleofection program T-16.  Cells were incubated for 
48h in complete medium, then serum-starved for 24h.  Luciferase activity was assessed in 
50µl of lysate following addition of luciferase substrate (Promega) and normalized to total 
protein content in the sample.   
vIL-6 protein detection in KSHV-positive BCP-1 cells 
6 x106 BCP-1 cells(25) were transfected with 5µg K15 expression construct or pFJAE vector 
as a control using the human B cell nucleofection kit (Amaxa) and the nucleofection 
program T-16.  Cells were incubated for 48h in complete medium.  10µg total protein per 
sample were separated by electrophoresis through an 8% SDS-PAGE gel.    Protein was 
transferred to nitrocellulose membranes.  The viral IL-6 protein and exogenous Flag-tagged 
 52 
 
K15 proteins were detected with rabbit anti-vIL6 antibody (Advanced Biotechnologies) 
followed by HRP-conjugated anti-rabbit IgG or HRP-conjugated anti-ECS antibody (Bethyl) 
respectively.  
Results 
Expression of K15 in BJAB cells 
Multiple K15 isoforms have been identified as the result of alternative splicing of the K15 
mRNA (14, 29, 65).  The four isoforms described by Choi, et al are referenced here.  The 
largest isoform, Clone 35, has a reported molecular weight of 49-55 kDa when ectopically 
expressed in epithelial cells (3, 14).  The smaller isoforms, Clones 1, 15 and 20, have 
predicted molecular weights of 42 kDa, 31 kDa and 28 kDa respectively (14).  KSHV-
negative B lymphoma cells  (BJAB) were transfected with cDNA constructs of four 
alternatively spliced Flag-tagged K15 isoforms (Clone 1, 15, 20 or 35) or a genomic Flag-
tagged K15 construct (Figure 2.1A).  At 48h after transfection, BJAB cells were harvested, 
lysed and subjected to SDS-PAGE followed by Western blot with an antibody against the 
Flag epitope-tagged K15 constructs.  In the case of BJAB cells transfected with K15 cDNA 
constructs, major protein bands were detected that were consistent with previous reports 
(Figure 2.1B).  Specifically, a protein band of approximately 50 kDa was detected in cells 
transfected with Clone 35, whereas 45 kDa, 39 kDa and 35 kDa bands were detected in 
BJAB cells transfected with Clone 1, 15, or 20 respectively.  None of these bands were 
detected in BJAB cells transfected with a vector control.  In BJAB cells transfected with the 
genomic K15 construct, all four isoforms were detected with the two largest isoforms (Clone 
35 and Clone 1) expressed preferentially.  The smaller isoforms could only be detected after 
long exposure times.  
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Cytokine profile of K15-expressing B cells 
Since K15 is a membrane protein expressed on the cell surface and is capable of 
initiating signal transduction cascades, including activation of both the MAPK and NF-κB 
pathways (3, 14, 88), we sought to determine whether K15 caused any changes in the 
cytokine milieu when expressed in B lymphocytes.  To this end, BJAB cells were transfected 
with the genomic K15 construct or a vector control.  Following 24h of serum starvation, 
conditioned medium was collected.  The presence of 84 cytokines was assessed by an 
antibody array.  Indeed K15 caused multiple perturbations in the cytokine environment, 
 
 
Figure 2.1  Expression of K15 in BJAB cells.  A)  At least four K15 isoforms arise from 
multiple alternative splicing events.  B) The Flag-tagged K15 cDNA expression constructs Clone 
1, Clone 15, Clone 20, and Clone 35 or the genomic K15 construct were transfected into BJAB 
cells.  K15 was detected in cellular lysates by immunoblotting with an anti-ECS antibody to 
detect the Flag epitope tag. 
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including at least 2-fold increases in GRO, IL-2Ra, IL-6,  IL-12 p40, IL-17, I-309, IGFBP-1, 
leptin, MCP-1, MCP-2, MCP-3, MIP-3b, MSP-1, NT-4, Osteoprotegrin, Oncostatin M, PDGF-
BB, PIGF, TRAIL R4, sTNFRI, sTNFRII, and VEGF-D  (Table 1).  K15-expressing BJAB 
cells also exhibited at least a 2-fold decrease in the expression of some cytokines, including 
Eotaxin, ICAM-1 and BTC (Table 2.1).  Given that there are high levels of circulating IL-6 
found in KSHV-associated malignancies and the demonstrated role for both viral IL-6 (vIL-6) 
and human IL-6 (hIL-6) in PEL (12, 20, 23, 36, 59), we pursued human IL-6 as an important 
downstream target of K15 signaling.   
 
            Table 2.1 K15 alters cytokine expression in BJAB cells 
 
Growth Factor/ 
Cytokine 
Fold Change  Growth Factor/ 
Cytokine 
Fold Change 
Eotaxin -9.6  sTNFRII 2.3 
ICAM-1 -4.8  IGFBP-1 2.5 
BTC -3.3  MIP-3b 2.6 
MCP-2 2.0  TRAIL R4 2.7 
VEGF-D 2.0  Osteoprotegrin 2.9 
IL-12 p40 2.0  NT-4 3.0 
sTNF-RI 2.0  Oncostatin M 3.2 
GRO 2.0  IL-6 3.6 
MCP-1 2.0  MSP-1 4.6 
leptin 2.1  IL-17 8.3 
IL-2Ra 2.2  PIGF 8.3 
I-309 2.2  MCP-3 20.7 
PDGF-BB 2.3    
K15 expression upregulates hIL-6 in BJAB cells 
In order to confirm that K15 expression increases hIL-6 expression, an ELISA for 
hIL-6 was performed using conditioned medium collected from BJAB cells expressing K15 
cDNA constructs or a vector control (Figure 2.2A).  When expressed individually, all four 
K15 constructs increased hIL-6 expression, although to varying degrees.  In one 
representative experiment, K15 Clone 1, 15, 20, and 35 showed 3.9-, 10.1-, 10.3-, and 5.3-
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fold increases in hIL-6 secretion respectively, as compared to the vector control (Figure 
2.2A).  In repeated experiments, the smaller K15 clones 15 and 20 exhibited the greatest 
induction of hIL-6 secretion.   
K15 increases gene expression levels of human IL-6 in BJAB cells 
In order to determine if IL-6 is regulated by K15 at the level of transcription, RNA 
was isolated from BJAB cells expressing a K15 cDNA construct, a genomic K15 construct or 
a vector control.  IL-6 mRNA levels were assessed by RT-PCR (Figure 2.2B).  Although all 
four K15 isoforms could increase IL-6 expression, the smaller K15 isoforms exhibited the 
most dramatic increases in IL-6 mRNA (Figure 2.2B).  When normalized to β-actin and as 
compared to the vector control, K15 Clone 1, Clone 15, Clone 20 and Clone 35 increased 
mRNA levels by 4.7-fold, 11.1-fold, 6.8-fold and 2.2-fold respectively.  In contrast, no IL-6 
was detected in the “no RT” controls.  Furthermore, all four K15 isoforms drove expression 
of a luciferase reporter gene, that was cloned downstream of the full-length hIL-6 promoter 
(p1168huIL6P-luc+).  As compared to the empty vector control, K15 clones 1, 15, 20 and 35 
activated the hIL-6 promoter four- to six-fold (Figure 2.2C).   Additionally, the K15 genomic 
construct activated the hIL-6 promoter nearly seven-fold as compared to its vector control 
(Figure2.2C).  Since the genomic K15 construct behaved similarly to the K15 cDNA 
constructs in both direct measurement of IL-6 expression and in reporter assays, the 
genomic K15 construct was used for all subsequent experiments.  
K15-mediated IL-6 expression leads to hyperphosphorylation of STAT1 
 IL6-IL6 receptor signaling has previously been shown to activate the JAK/STAT 
pathway resulting in the activation of signal transducer and activator of transcription 1 
(STAT1) (28, 46).  Thus, we investigated K15’s ability to activate the downstream IL-6  
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Figure 2.2  K15 induces the expression of cellular interleukin-6 in B lymphocytes.  
Interleukin-6 (IL-6) was one of many cytokines and growth factors induced by a genomic K15 
construct in BJAB cells as identified by a cytokine expression array.  The induction of IL-6 by the 
smaller K15 isoforms and the genomic K15 construct was confirmed by ELISA (A), RT-PCR (B), 
and IL-6 promoter luciferase reporter assays (C).  
  
 57 
 
signaling molecule STAT1.  Serum-starved BJAB cells transfected with K15 cDNA 
constructs or a vector control were lysed and subjected to SDS-PAGE followed by 
immunoblot using antibodies that specifically react with STAT1 or activated phosphoTyr701-
STAT1.  Increased levels of phosphorylated STAT1  (218-378% as compared to the vector 
control) were detected in cells expressing K15 as compared to the vector control, although 
no changes in total STAT1 were evident (Figure 2.3).    
 
 
K15-mediated IL-6 upregulation requires K15 signaling 
Since K15 mediates IL-6 upregulation at the transcriptional level, we investigated the 
requirement for K15 signaling.  K15 is a membrane protein expressed on the cell surface 
and the cytoplasmic tails of all K15 isoforms contain highly conserved putative signaling 
motifs (29).  It has been previously reported that K15 mobilizes multiple transcription factors 
Figure 2.3 K15 expression results in hyperphosphorylation of STAT1.  K15 expression in B 
cells causes hyperphosphorylation of the activating tyrosine residue 701, and to a lesser extent 
of the serine residue 727, of the Signal Transducer and Activator of Transcription-1 (STAT1).  
STAT1 is a downstream effector of the IL-6/JAK-STAT signaling axis.  Thus, its activation may 
be a result of IL-6 overexpression. 
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including AP-1 and NF-κB in epithelial cells and that the putative SH2 binding site is 
important for its signaling functions (3, 88).  We first determined if K15 expression activates 
NF-κB signaling pathways in B lymphocytes by co-transfecting a genomic K15 expression 
construct or a vector control with an NF-κB –responsive luciferase plasmid (Figure 2.4A).  
Expression of the genomic K15 construct invoked a 2.6-fold increase in NF-κB-driven 
luciferase activity as compared to a vector control.  Thus, K15’s ability to activate NF-κB in B 
lymphocytes is lower than in epithelial cells (3). Mobilization of AP-1 transcription factors 
was also examined by co-expression of a genomic K15 expression construct or a vector 
control with a luciferase reporter plasmid containing a TPA-responsive element (TRE) in the 
promoter (Figure 2.4A).  AP-1 activity, as determined by the TRE-luciferase construct, was 
3.6-fold higher in BJAB cells expressing the genomic K15 construct as compared to the 
vector control. 
 Tyrosine residue 481 in the cytoplasmic tail of K15 has been shown to be important 
for NF-κB and AP-1 signalling in epithelial cells (3, 88).  Therefore, we examined if tyrosine 
residue 481 is a requirement for K15-mediated NF-κB and AP-1 activation.  The full length 
K15 isoform (Clone 35), a full length K15 isoform with the tyrosine 481 residue mutated to 
phenylalanine (K15 Y481F), or a pFJ vector control was transfected into BJAB cells with an 
NF-κB responsive luciferase reporter or with the TRE-luciferase construct.  Expression of 
the full length wild-type K15 Clone 35 resulted in a 2.1-fold increase in NF-κB driven 
luciferase activity as compared to the vector control, while K15 Y481F showed no increase 
in NF-κB activity (Figure 2.4B).  Similarly, K15 Clone 35 caused an 8.4-fold increase in AP-1 
activity in contrast to the K15 Y481F mutant which exhibited a minor increase (1.6-fold) as 
compared to the vector control (Figure 2.4B).    
Finally, to determine if signaling through the putative SH2 binding site in the 
cytoplasmic tail of K15 is necessary for activation of the cellular IL-6 promoter, the K15 
Clone35, K15 Y481F, or a pFJ vector control was transfected into BJAB cells with the full- 
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length IL-6 promoter luciferase reporter plasmid.  A luciferase assay was performed (Figure 
2.4C).  K15 Clone 35 induced a 5.7-fold increase in IL-6 promoter luciferase activity as 
compared to the vector control, whereas the K15 Y481F mutant exhibited a negligible 
increase in promoter activity (1.6-fold as compared to the vector control). 
Figure 2.4  Induction of IL-
6 by K15 is dependent on 
K15 signaling.  A) 
Activation of NF-κB and AP-
1 by K15 was determined by 
luciferase assay.   BJAB 
cells expressing K15 (gray 
bars) or a vector control 
(black bars) were 
cotransfected with an NF-
κB-responsive luciferase 
reporter plasmid or an AP-1 
responsive luciferase 
plasmid (TRE-luciferase).  
Results are presented as 
fold activation as compared 
to the vector control.  B)  An 
NF-κB-responsive luciferase 
construct (black bars) or an 
AP-1 responsive luciferase 
plasmid (gray bars) was 
transfected into BJAB cells 
expressing the wild-type full 
length K15 Clone 35 cDNA, 
a full length K15 Y481F 
mutant, or an FJ vector 
control.  Fold activation over 
the empty vector is reported 
for each of the reporter 
constructs.  C)  BJAB cells 
were transfected with the 
full length human IL-6 
promoter luciferase reporter 
construct and a wild-type full 
length K15 expression 
construct (Clone 35), a full 
length K15 expression 
construct with a mutation in 
the putative SH2 binding 
domain (K15 Y481F), or a 
vector control.  Activation of 
the promoter was measured 
by luciferase and is 
displayed as fold activation 
over the vector control.  
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Determination of the K15-responsive elements in the hIL-6 promoter 
To further define the K15-responsive elements in the hIL-6 promoter, we obtained 
several hIL-6 deletion and point mutant hIL-6 promoter luciferase reporter plasmids (Figure 
2.5A) from the Belgian Co-ordinated Collections of Micro-organisms/ LMBP Plasmid and 
DNA library collections (BCCM/LMBP) (84).  BJAB cells expressing K15 were co-
transfected with the deletion mutant hIL-6 promoter luciferase constructs.    Serum-starved 
cells were lysed and luciferase activity was determined.  No activation of the minimal 
promoter was evidenced by either K15 or the empty vector control (p50huIL6P-luc+) (Figure 
2.5B).  In general, K15-mediated IL-6 induction increased as more of the IL-6 promoter was 
incorporated into the luciferase reporter plasmid.  The p110huIL6P-luc+, p234huIL6P-luc+ 
and p1168huIL6P-luc+ constructs contained 100, 234 and 1168 nucleotides of the IL-6 
promoter inserted upstream of the luciferase gene, respectively.   Genomic K15 
transactivated the p110huIL6P-luc+ construct two-fold, the p234huIL6P-luc+ three-fold, and 
the p1168huIL6P-luc+ four-fold compared to the empty vector control (Figure 2.5B).    
Multiple transcription factors, but most notably NF-κB and AP-1, have been 
implicated in the upregulation of IL-6 in response to various stimuli (inflammatory cytokines, 
microbial pathogens, etc.) and in spontaneous tumor formation (13, 19, 37, 54, 58, 64, 84, 
86).  Importantly, upon infection of epithelial cells, KSHV activates AP-1 transcription factors 
(90).  In B lymphocytes, K15 signaling through tyrosine residue 481 activates AP-1 and NF-
κB transcription factors and is also required for K15-mediated human IL-6 promoter 
activation as shown in Figure 2.4.  Since K15 expression in B lymphocytes caused 
increases in both NF-κB and AP-1 activity, the proximal NF-κB and AP-1 transcription factor 
binding site mutants of the full length IL-6 promoter luciferase reporter construct were 
employed to further delineate K15-responsive elements.   BJAB cells were co-transfected 
with a K15 expression construct and an NF-κB or AP-1 mutant hIL-6 promoter luciferase 
plasmid.  Cells were serum-starved and luciferase activity was determined.  Human IL-6 
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promoter activity was diminished to near background levels with the 3’ AP-1 mutant but 
remained unchanged with the NF-κB promoter mutant in cells expressing K15 as compared 
to the empty vector controls (Figure 2.5C). 
 
 
 
  
Figure 2.5  Determination of K15-responsive elements in the human IL-6 promoter.  A) 
Deletion and point mutant human IL-6 promoter luciferase constructs were used to determine 
the K15-responsive elements in the human IL-6 promoter.  B)  Genomic K15 (black bars) or a 
vector control (gray bars) was expressed in BJAB cells along with a full length IL-6 luciferase 
reporter plasmid or deletion constructs containing 234 (p234huIL6p-luc+), 110 bp (p110huIL6p-
luc+), or 50bp (p50huIL6p-luc+) of the IL-6 promoter.  Results are expressed as RLU per µg 
protein.  Numbers above each pair indicate fold activation over the vector control.  C)  BJAB 
cells were transfected with a genomic K15 expression construct (black bars) or a vector control 
(gray bars) as well as full length IL-6 luciferase reporter plasmids.  Wild-type IL-6 promoter 
constructs and NF-κB or AP-1 mutant IL-6 promoter constructs were tested.  Results are 
expressed as fold activation over a matched vector control. 
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Investigation of a potential feedback loop with vIL-6 
KSHV encodes a viral IL-6 homolog (52).  Like K15, vIL-6 is detected in latency, but 
is upregulated during lytic reactivation (35, 63, 80).  It is highly expressed in PEL and has 
been reported to form an autocrine activation loop with hIL-6 (7, 51, 53, 60, 77).   Therefore, 
activity of the vIL-6 promoter was also assessed in K15-expressing BJAB cells.  A K15 
expression construct was co-transfected with a vIL-6 promoter luciferase reporter plasmid 
into BJAB cells.  Cells were serum-starved for 24 hours prior to lysis and measurement of 
luciferase activity.  K15 activated the vIL-6 promoter more than five-fold as compared to the 
vector control (Figure 2.6A).   
Next, to demonstrate that K15 enhances vIL-6 expression in naturally infected 
primary effusion lymphoma cells, a Flag-tagged genomic K15 expression construct or a 
vector control was transfected into the KSHV-positive PEL cell line, BCP-1.  Viral IL-6 
protein expression was assessed in cell lysates by immunoblotting with a vIL-6 specific 
antibody.  Introduction of the Flag-tagged genomic K15 construct into BCP-1 cells increased 
vIL-6 protein expression approximately two-fold in uninduced BCP-1 cells as compared to 
the vector control (Figure 2.6B). 
Figure 2.6  K15 expression in B cells induces expression of the viral IL-6 homolog.  A)  
BJAB cells expressing the genomic K15 construct or a vector control were transfected with a viral 
IL-6 promoter-responsive luciferase plasmid.  Luciferase activity is presented as fold activation 
over a vector control.  B)  Cells of the primary effusion lymphoma cell line BCP-1 were transfected 
with a Flag-tagged genomic K15 construct.  Lysates were subjected to SDS-PAGE, transferred to 
nitrocellulose, and vIL-6 and K15 proteins were detected with anti-vIL-6 antibody followed by 
HRP-conjugated anti-rabbit IgG or with an HRP-conjugated anti-ECS antibody respectively.    
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Discussion 
The KSHV K15 protein has been detected in primary effusion lymphoma cells and in 
plasmablasts isolated from patients with multicentric Castleman’s disease (74).  K15 has 
been characterized as a latent gene and has been shown to inhibit signaling through the B 
cell receptor (14, 29, 74).  In this chapter we have investigated the impact of K15 expression 
in B lymphocytes.  Earlier studies investigated the function of the individually spliced K15 
isoforms in various assays.  Here we have created and characterized a genomic K15 
expression construct which expresses multiple isoforms in the same cell and may be more 
physiologically relevant.  While all four K15 isoforms could be detected in B lymphocytes 
transfected with the K15 genomic construct, Clone 35 (49 kDA) and Clone 1 (45 kDa) were 
expressed at much higher levels than the smaller isoforms Clone 15 (39 kDa) and Clone 20 
(35 kDa), indicating that either the larger isoforms are preferentially transcribed or that the 
smaller isoforms are less stable and are rapidly degraded.  Similar to the larger K15 
isoforms, the smaller isoforms induced IL-6 transcription and secretion when expressed 
individually in B lymphocytes, indicating that they are functionally active. 
A hallmark of all three KSHV-associated malignancies is the dysregulation of 
multiple cytokines and growth factors (16, 20, 21, 36, 50, 52, 59, 61, 71, 72, 79).  Cytokine 
and growth factor expression levels can be quickly altered to respond to environmental 
cues.  Stimulus of a cellular receptor poised to detect changes in either the intracellular or 
the extracellular environment initiates a signaling cascade which culminates in induction or 
supression of the appropriate cytokines.  Given the localization and signaling properties of 
K15, we hypothesized that K15 signaling may result in changes in the cytokine environment.  
We used a cytokine antibody array to characterize the changes in cytokine expression 
resulting from expression of the genomic K15 construct in B lymphocytes.  In BJAB cells, 
K15 induced the expression of GRO, IL-2Ra, IL-6,  IL-12 p40, IL-17, I-309, IGFBP-1, leptin, 
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MCP-1, MCP-2, MCP-3, MIP-3b, MSP-1, NT-4, Osteoprotegrin, Oncostatin M, PDGF-BB, 
PIGF, TRAIL R4, sTNFRI, sTNFRII, and VEGF-D.  IL-6, MCP-1, MIP3α and GRO3 
cytokines were similarly induced in epithelial cells (4).  However, K15 did not elicit IL1α/β or 
IL-8 in B cells as in epithelial cells, suggesting that regulation of cytokine expression by K15 
may be cell-type specific (4).   
IL-6, IL-10, VEGF and Oncostatin M (OSM) are upregulated in PEL and MCD (1, 20, 
22, 36, 59).   IL-6 and OSM are members of the same cytokine family, initiating signaling 
cascades through interaction with a specific receptor and the common gp130 subunit (27, 
44, 81).  Cellular IL-6 binds to the IL6 receptor alpha (IL6-Rα)-gp130 complex to initiate 
signaling via the JAK-STAT pathway (24, 32, 34, 39, 40, 45, 46, 81, 83).  IL-6 and OSM are 
potent mitogens of KSHV-infected cells (6, 23, 50) and may protect the infected cell from 
programmed cell death.  Of note, expression of IL-6, VEGF and OSM was positively 
regulated by K15 in the cytokine array analysis.  Thus, K15 expression in the context of viral 
infection may ensure survival of the infected cell by release of cytokines with anti-apoptotic 
and proliferative end effects.    
As the role of IL-6 in viral infection is well documented, we investigated the 
mechanism by which K15 upregulates IL-6 expression.  Four cDNA constructs of K15 were 
assessed individually for their ability to induce IL-6 expression.  The four isoforms caused 
variable increases in IL-6 secretion as determined by ELISA, with IL-6 levels apparently 
inversely related to the level of K15 expression as determined by Western blot.  Increases in 
IL-6 transcription as determined by RT-PCR and IL-6 promoter luciferase reporter assays 
did not exhibit the same inverse relationship to the isoform expression levels.  This suggests 
that all four isoforms are similarly capable of signal transduction, but that the isoforms may 
differentially regulate protein translation or secretion.  More likely the variable levels of 
secreted IL-6 may have been caused by functional impedance and an artifact of 
overexpression, since 2 µg of K15 Clone 35 cDNA enhanced IL-6 production as compared 
 65 
 
to 5 µg, achieving levels similar to those induced by the smaller isoforms when transfected 
into B lymphocytes (data not shown).  
We argued that the genomic K15 construct was likely to be more physiologically 
relevant than using any individual cDNA construct, since relative expression of the isoforms 
was likely similar to natural infection and would represent the overall effect of K15 
expression in the B lymphocyte.  Furthermore, since all four isoforms and the genomic K15 
construct exhibited similar effects with respect to IL-6 expression, we used the genomic K15 
construct to further investigate the mechanism of regulation.  Using a panel of deletion 
mutants of the IL-6 promoter luciferase reporter plasmids, we determined that the shortest 
fragment activated by K15 contained an NF-κB and an AP-1 transcription factor binding site.  
Longer IL-6 promoter fragments further increased activity of the luciferase reporter.   
It had previously been reported that NF-κB and AP-1 are important for IL-6 promoter 
activation by various stimuli (19, 37, 58, 90).  We found that K15 can activate both 
transcription factors in B lymphocytes.  However, NF-κB induction was muted in B cells as 
compared to epithelial cells (3) and may reflect a constitutively high background level of NF-
κB activity in BJAB cells (2).  In epithelial cells, K15-mediated activity of NF-κB and AP-1 
transcription factors was dependent on the tyrosine 481 residue (3, 88).  We determined 
that this residue was also required for NF-κB and AP-1 activity in B lymphocytes, further 
underscoring the importance of this signaling domain to K15 function.  
After determining that K15 was capable of activating NF-κB and AP-1 in B cells, we 
used a cadre of IL-6 promoter mutants and a signaling incompetent K15 construct to explore 
the roles of these signaling moieties in K15-mediated IL-6 induction.  The K15 Y481F 
mutant did not induce IL-6 promoter activity, suggesting that the signal transduction 
cascades initiated by this domain are central to the upregulation of IL-6 by K15.  The 
tyrosine residue of this putative SH2 domain was also required for NF-κB and AP-1 driven 
promoter activity.  However, mutation of the NF-κB site in the IL-6 promoter did not 
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significantly affect induction of the promoter in response to K15.  In contrast, mutation of the 
3’AP-1 responsive element in the IL-6 promoter ablated promoter activity.  Together these 
data suggest that K15 initiates signaling cascades in B cells that activate AP-1 transcription 
factors resulting in the upregulation of cellular IL-6 expression.  K15-mediated NF-κB 
activation may augment but is not required for IL-6 promoter activity.  Emphasizing the 
importance of this finding, KSHV mobilizes AP-1 transcription factors resulting in 
upregulation of  IL-6 expression within six hours after infection of epithelial cells (90).   
In addition to stimulating cellular IL-6, KSHV encodes its own viral IL-6 homolog (vIL-
6) that is highly expressed in PEL and MCD (7, 52, 63, 77).  vIL-6 is primarily a lytic 
transcript and its expression is very highly induced during viral reactivation, although low 
levels of this protein are detected during latency (63, 80).   We found that K15 increased 
vIL-6 promoter activity in BJAB cells, indicating that K15 not only induces cellular IL-6, but 
can also upregulate viral IL-6 transcription.  We further demonstrated that introduction of 
exogenous K15 increases vIL-6 protein expression in the KSHV-positive primary effusion 
lymphoma BCP-1 cell line.  vIL-6 drives PEL cell proliferation similarly to cellular IL-6 (12, 
23, 36).  Therefore K15 may also indirectly contribute to survival of KSHV-infected cells, by 
stimulating expression of vIL-6.  What is more, vIL-6 interacts directly with the gp130 signal 
transducer without the need for a specific receptor, in contrast to IL-6 and OSM (51, 53, 60, 
87).  Since gp130 is ubiquitously expressed, the effects of vIL-6 are potentially more 
widespread and not restricted to cells expressing specific receptors.  Thus, K15-mediated 
induction of vIL-6 may also serve to stimulate proliferation of uninfected cells in the 
extracellular milieu. 
The high levels of IL-6 expression in KSHV-associated malignancies and the fact 
that the virus encodes an IL-6 homolog underscore the importance of this cytokine and 
downstream IL-6 effectors in viral pathogenesis.  IL-6 signaling has been shown to result in 
activation of the JAK-STAT pathway (28, 46).  We examined downstream signaling 
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molecules and observed that activated signal transducer and activator of transcription 
(STAT) 1 is differentially expressed in BJAB cells transfected with K15.  Although IL-6 
reportedly activates both STAT1 and STAT3, its proliferative and anti-apoptotic effects are 
more commonly associated with STAT3, whereas STAT1 is more commonly associated 
with an interferon-induced antiviral response (15, 33, 67).  Thus the increase in activated 
STAT1 with stable levels of activated STAT3 in K15-expressing cells was perplexing.   
Many viruses have devised immune evasion strategies including degradation of 
STAT1, inhibition of STAT1 activation, and sequestration of STAT1 outside the nucleus (5, 
18, 26, 30, 38, 42, 43, 56, 62, 66, 69, 82, 85, 89).  We found that in B cells expressing K15, 
phosphorylated STAT1 did not directly interact with K15 and was present at increased levels 
in both cytoplasmic and nuclear fractions (unpublished data) arguing against sequestration.  
Furthermore, K15 expression did not interfere with a Type I interferon response 
(unpublished data) indicating that STAT1 activity was intact.  Thus, K15 does not inhibit 
classic STAT1 functions and its activation is likely to play a more integral role in KSHV 
pathogenesis.   
Despite the large arsenal of STAT-1 inhibitory mechanisms employed by viruses, 
induction of and benefit from STAT1 activation have also been reported.  In fact, the latent 
membrane protein (LMP) 1 and SM protein of the closely related Epstein Barr virus also 
stimulate STAT1 activation (57, 68, 70), but may induce a form of STAT1 that is distinct 
from the form integral to the antiviral response (48).  STAT1 may also serve as a scaffolding 
protein to orchestrate multiple downstream signaling events (76).  Furthermore, the function 
of STAT1 may be modulated by heterodimerization with the pro-survival and growth 
stimulatory STAT3 protein (31).  In fact, the viral IL-6 homolog of KSHV initiaties JAK-STAT 
signaling that results in STAT1/STAT3 heterodimerization (51).  Therefore, K15’s ability to 
induce STAT1 is likely IL-6 dependent, but may also result from other cytokines, such as 
OSM, that are induced by K15 (76).  Future studies exploring protein-protein interactions 
 68 
 
and the DNA-binding properties of STAT1 in B lymphocytes expressing K15 will be 
necessary to define the functional consequences of IL-6/JAK-STAT signaling in the context 
of infection. 
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Abstract 
Kaposi’s sarcoma-associated herpesvirus (KSHV) encodes multiple isoforms of the K15 
transmembrane protein.  Full length K15 is predicted to contain twelve membrane-spanning 
domains.  Smaller isoforms contain fewer membrane domains but also localize to cellular 
membranes.  All isoforms share identical cytoplasmic tails that contain conserved signaling 
motifs.  K15 is expressed in the two B cell malignancies linked to KSHV, including primary 
effusion lymphoma (PEL) and the lymphoproliferative disorder, multicentric Castleman’s 
disease (MCD).  Cytokines are likely to play an important role in disease progression in 
MCD and in PEL.  In particular, interleukin-6 (IL-6) is highly expressed in all KSHV-
associated tumors.  We previously observed that K15 signaling induces multiple cytokines, 
most notably IL-6, when expressed ectopically in B lymphocyte cells.  In order to determine 
the consequences of K15 expression in the KSHV-infected cell, we constructed a 
KSHV∆K15 mutant virus using the KSHV bacterial artificial chromosome (BAC) system.  We 
examined IL-6 expression, proliferation rates and viral loads of cells harboring the WT-
KSHV or KSHV∆K15-BAC.  We found that IL-6 secretion was significantly higher in cells 
transfected with the WT-KSHV BAC.  Although K15 had no effect on proliferation rate of a 
transformed B lymphocyte cell line, in the absence of K15 higher cell-free viral loads were 
achieved, suggesting that K15 may promote latency in B cells. 
Introduction 
The Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human 
herpesvirus-8, has been linked to Kaposi’s sarcoma (KS)(9), primary effusion lymphoma 
(PEL)(7), and the plasmablastic variant of multicentric Castleman’s disease (MCD)(52).  The 
virus poses a significant threat to immunocompromised populations, as the KSHV-
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associated malignancies are more common in post-transplant patients and patients with 
AIDS (7, 8, 32, 38, 52).  Treatment is typically palliative not curative (reviewed in (25)).   
In an otherwise healthy host, KSHV establishes persistent infection via a highly 
complex and poorly understood process.  After primary infection, the virus establishes 
latency and persists in a quiescent state, with only a few viral genes expressed (22, 48, 54, 
64).  KS tumors are comprised mainly of KSHV-infected spindle cells of endothelial origin (2, 
55, 64), whereas KSHV-infected B lymphocytes are the oncogenic source of PEL and MCD 
(7, 52).  While the majority of infected cells in all three malignancies remain latent, a small 
percentage of cells undergo spontaneous lytic replication at any given time (64).   
Inflammatory cytokines contribute to viral pathogenesis.  Infiltrating inflammatory 
cells secrete numerous cytokines, such as IL-1α, IL-6, Oncostatin M, TNFα, TNFβ, and IFNγ 
that stimulate spindle cell formation and proliferation in KS (5, 14, 15, 34, 41, 51, 56).  
Angiogenic cytokines such as VEGF and bFGF play an important role in the highly 
vascularized KS lesions (12, 45-47).  In PEL and MCD, IL-6 and IL-10 are expressed at high 
levels (13, 16, 23, 39).  Additionally, VEGF and Oncostatin M are also produced by PEL 
cells (1, 13).  IL-6 and VEGF were found to be necessary to stimulate the growth of PEL 
cells injected into SCID mice (1, 17).   
In addition to cytokines released from inflammatory cells, KSHV encodes a viral IL-6 
homolog (vIL-6) that is expressed at high levels in PEL and MCD (6, 36, 42, 53).  vIL-6 can 
bind directly to the gp130 coreceptor molecule to initiate JAK-STAT signaling, thereby 
bypassing the need for the IL-6 receptor sub-unit (35, 37, 40, 59).  The expression of vIL-6 
further enhances IL-6 signaling and drives PEL cell proliferation (10, 23).  Furthermore, viral 
proteins such as K1 and K15 have been shown to induce expression of inflammatory 
cytokines when expressed ectopically in cell culture.  For instance, K1 stimulates VEGF 
expression in endothelial cells, suggestive of a role in neovascularization (62).  Injection of 
K1-expressing C33A cells into nude mice resulted in highly vascularized lesions(61).  The 
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expression of K15 in HeLa epithelial cells induced expression of IL-8, IL-6, CCL2, CCL20, 
IL1α/β, and CXCL3 (4).  We have seen that K15 expression in B lymphocytes leads to 
overexpression of numerous cytokines, including GRO, IL-2Ra, IL-6,  IL-12 p40, IL-17, I-
309, IGFBP-1, leptin, MCP-1, MCP-2, MCP-3, MIP-3b, MSP-1, NT-4, Osteoprotegrin, 
Oncostatin M, PDGF-BB, PIGF, TRAIL R4, sTNFRI, sTNFRII, and VEGF-D.   
The K15 open reading frame (ORF) encodes multiple K15 isoforms, stemming from 
alternatively spliced transcripts (11, 19, 44).  The isoforms encode a variable number of 
transmembrane domains, but they all maintain identical cytoplasmic tails that contain 
several conserved signaling motifs, including potential SH2, SH3 and TRAF binding sites (3, 
29, 44, 60).  The tyrosine 481 residue, which is incorporated into both the SH2 binding 
domain and the TRAF binding site, is particularly important for K15 signaling functions in 
epithelial as well as B lymphocyte cells.   
In the setting of natural infection, K15 expression has been detected in the two 
KSHV-associated B cell malignancies—in PEL cells and in plasmablasts of MCD (49).  K15 
transcripts have been detected in unstimulated PEL cells (11, 19, 44).  However, the K15 
promoter is responsive to the viral lytic switch protein and K15 transcripts increase upon 
induction of the lytic cycle by phorbol esters (4, 11, 19, 63).  A 23 kDa protein was detected 
in BCBL-1 PEL cells using an antibody raised to the cytoplasmic tail of the K15 protein (49).  
A 45 kDa protein consistent in size with the full-length K15 protein was detected in epithelial 
cells transfected with a KSHV bacterial artificial chromosome containing the entire KSHV 
genome, and its expression increased upon induction of lytic replication (4).   
In this chapter, we describe the construction of a KSHV∆K15 bacterial artificial 
chromosome (BAC) that was used to determine the function of the K15 protein in the 
context of the virus.  IL-6 concentrations in uninduced B lymphocytes containing the 
KSHV∆K15-BAC were not measurable but reached 4.5 pg/ml in cells containing the wild-
type KSHV-BAC.  IL-6 expression and secretion was impaired two-fold in KSHV∆K15-BJAB 
 81 
 
cells as compared to the WT KSHV-BJAB cells when the lytic cycle was induced with 
phorbol 12-myristate 13-acetate (PMA/TPA).   BJAB cells transfected with the KSHV-WT 
and KSHV∆K15 bacterial artificial chromosomes showed similar growth and survival 
patterns.  However, the introduction of the KSHV∆K15 virus into BJAB cells achieved higher 
cell free viral loads than the introduction of the KSHV-WT virus, suggesting that K15 may 
regulate lytic reactivation and promote viral latency. 
Materials and Methods 
Creation of the KSHV∆K15 bacterial artificial chromosome 
 The wild-type KSHV bacterial artificial chromosome (WT KSHV-BAC) has been previously 
described(65).  Briefly, the WT KSHV-BAC contains the entire viral genome, a green 
fluorescent protein expression cassette under control of a constitutive promoter, and a 
hygromycin resistance gene.  Therefore, cells harboring the virus fluoresce green and 
survive hygromycin B selection in mammalian cells.  To create the KSHV∆K15-BAC, a 
kanamycin resistance (KanR) gene expression cassette was inserted into the open reading 
frame (ORF) of the K15 gene by homologous recombination.  The KanR cassette was 
amplified from the pKD13 plasmid, and was extended with flanking regions homologous to 
the K15 ORF.  The PCR product was cleaved with DpnI to remove any input template DNA, 
and then gel purified from a 0.8% agarose gel.   For KSHV∆K15#3, the forward primer 
contained the sequence corresponding to nucleotides 134831-134880 of the KSHV viral 
genome (Genbank accession number NC_009333), the reverse primer corresponded to 
nucleotides 136841-136870.  For KSHV∆K15#4 the forward primer corresponded to 
nucleotides 134911-134960 of the viral genome, while the reverse primer corresponded to 
nucleotides 136751-136800.  Finally, for KSHV∆K15#5 the forward primer corresponded to 
nucleotides 134981-135030, while the reverse primer corresponded to nucleotides 136681-
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136730.  Homologous recombination was stimulated by growth at 42˚C of the EL350 E. coli 
strain transformed with the WT KSHV-BAC and the respectively cloned KanR cassette with 
K15-homologous flanking regions.  Cells were plated on LB-agar plates containing 12.5 
µg/ml chloramphenicol and 50 µg/ml kanamycin and grown at 30˚C to select for mutants.  
To confirm insertion of the kanamycin expression cassette and deletion of the K15 ORF, WT 
KSHV-BAC and KSHV∆K15-BAC DNA was subjected to restriction enzyme digestion with 
FmpI, StuI, or MfeI + EcoRI.  Digested fragments were resolved by 2% agarose gel 
electrophoresis and ethidium bromide staining.   
Southern Blot 
DNA fragments of PstI-digested WT KSHV-BAC and KSHV∆K15-BAC DNA were separated 
by agarose gel electrophoresis and transferred to nylon membrane by capillary action. 
Membranes were labeled with a radioactive probe complimentary to the kanamycin gene or 
to the undeleted 3’-end of the K15 ORF (corresponding to nt134713-135113 of the 
GenBank accession number NC_009333) and  were exposed to a phosphorimaging screen.  
Detection of the recombined DNA was performed with a phosphorimager.  
WT KSHV-BJAB and KSHV∆K15-BJAB stable cell formation 
WT KSHV-BAC and KSHV∆K15-BAC DNA was amplified in EL350 E.coli cells grown at 
30˚C overnight in the presence of 12.5 µg/ml chloramphenicol only (WT KSHV-BAC) or 
chloramphenicol and 50 µg/ml kanamycin (KSHV∆K15-BAC).  BAC DNA was isolated using 
the PhasePrep BAC DNA kit (Sigma).  BJAB cells were transfected with 5 µg of the KSHV 
wild-type bacterial artificial chromosome or 5 µg of the KSHV∆K15 #3 bacterial artificial 
chromosome using the human B cell nucleofection kit (Amaxa) and nucleofection program 
T-16.  Following transfection, cells were grown 48h in RPMI-1640 medium supplemented 
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with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin.  At 48h post-
transfection, growth medium was additionally supplemented with 0.2 mg/ml hygromycin B 
(Cellgro).  Cells were passaged in selection medium for at least two weeks and ≥90% of 
cells expressed green fluorescent protein, indicating the presence of the virus in those cells. 
Cell maintenance 
BJAB (KSHV-negative B cell lymphoma) cells (33) were maintained in RPMI-1640 medium 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL 
streptomycin.   Growth medium and supplements were obtained from Cellgro. 
RT-PCR 
Following 24h serum starvation and PMA/TPA treatment, RNA was isolated from KSHV-
BJAB stable cells using an RNeasy (Qiagen) RNA isolation kit.  1µg RNA was reverse 
transcribed with the Reverse Transcription System (Promega).  PCR was performed with 
the following primer pairs:  β-actinF 5’- GGCATCGTGATGGACTCCG-3’ and β-actinR 5’- 
GCTG GAAGGTGGACAGCGA-3’, K15 SeqF2 5’-GCTGTGTTGATGACAAACATGCTGG-3’ 
and K15 SeqR2 5’- GACTTAATCCTGCAGCGGTGG-3’, or IL6F 5’-
GGTACATCCTCGACGGCA TCTC-3’ and IL6R 5’-GTTGGGTCAGGGGTGGTTATTG-3’, or 
ORF75flF 5’-ATGGCCTACG ACGTCACTG-3’ and ORF75flR 5’-
TTAGTGGTGGTCGTTGATCTTCT-3’.  Products were resolved by agarose gel 
electrophoresis and visualized with ethidium bromide staining. 
Detection of K15 expression in KSHV-BJAB cells  
KSHV-BJAB cells were treated with 25 ng/ml phorbol 12-myristate 13-acetate (PMA/TPA) or 
a vehicle control for 24h.  Cells were lysed in RIPA buffer, subjected to SDS-PAGE and 
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transferred to nitrocellulose membranes for detection of K15 proteins with a polyclonal 
antibody (UNC221) raised in rabbits immunized with a K15 C-terminal peptide. 
IL-6 ELISA 
WT KSHV-BJAB and KSHV∆K15#3-BJAB stable cells were treated with PMA/TPA and 
serum starved for 24h.  Conditioned growth medium was collected from the cells and 
centrifuged to remove cellular debris.  Secreted IL-6 was detected using a typical sandwich 
ELISA (eBioscience) as per manufacturer’s instructions.   
KSHV-BJAB growth curve 
WT KSHV-BJAB and KSHV∆K15#3-BJAB stable cells were maintained in culture for 20+ 
passages.  ≥90% of cells continued to express GFP, indicating the viral genome was 
maintained in the majority of cells in each population. 48h prior to beginning the growth 
curve experiment, both cell lines were seeded at 3 x 105 cells/ml.  On day 0, cells were 
recounted and seeded at 5 x 104 cells/ml in 3 ml RPMI-1640 medium supplemented with 2% 
fetal bovine serum (RPMI-2%).  On days 3 and 5, culture volumes were increased to 6 ml 
and 18.5 ml with RPMI-2% in order to keep the cells in log growth phase.   Each day, live 
and dead cells were counted by the trypan blue exclusion method.   
Real-Time QPCR viral load assay 
Total DNA (viral and cellular) was isolated from WT KSHV-BJAB and KSHV∆K15#3-BJAB 
cells using the Genomic DNA wizard kit (Promega) as per manufacturer’s instructions.  
Conditioned medium was also collected.  Equal volumes of resuspended total DNA or 
conditioned medium from each of the KSHV-BJAB cell cultures was used as template for 
real-time QPCR viral load assays.  The real-time QPCR viral load assay detects viral 
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genomes using primers that anneal to the K49 ORF.  For cell-associated viral loads, primers 
annealing to the cellular GAPDH gene were used to determine the number of viral genomes 
per cellular genome.  Standard curves were derived from serially diluted K49 and GAPDH 
expression plasmids with known copy number.   
Results 
Creation of the KSHV∆K15 bacterial artificial chromosome 
The wild-type KSHV bacterial artificial chromosome (BAC) (65) is easily manipulated 
and therefore is a useful tool to investigate viral gene function in the context of viral 
infection.  We created three KSHV∆K15-BACs to determine the relevance of the K15-
mediated IL-6 induction in the context of viral infection.  A Kanamycin resistance expression 
cassette (KanR) was PCR amplified from the pKD13 plasmid using primers complimentary to 
the KanR cassette at the 3’ ends and complimentary to the K15 ORF at the 5’ ends of each 
primer, so that at either end the amplified KanR cassette is homologous to the region of K15 
that will be deleted.  The PCR product was then introduced into EL350 E. coli cells 
containing the KSHV wild-type BAC (WT KSHV-BAC).  Homologous recombination was 
stimulated by growth of the bacteria at 42˚C.  Recombinants were selected on agar 
containing kanamycin (Figure 3.1A). 
To confirm deletion of the K15 ORF, KSHV∆K15-BAC or WT KSHV-BAC DNA were 
subjected to restriction enzyme digestion with the following enzymes or enzyme pair:  FspI, 
StuI, or MfeI + EcoRI.  Digested DNA was resolved by agarose gel electrophoresis and 
ethidium bromide staining (Figure 3.1B).  A new FspI restriction enzyme site was introduced 
into the KSHV∆K15-BACs, such that a 13 kb band in the WT KSHV-BAC was replaced by 
10.5 kb and 1804 bp fragments in KSHV∆K15#3-BAC, by 10.6 kb and 1884 bp fragments in 
KSHV∆K15#4-BAC, and by 10.7 kb and 1954 bp fragments in KSHV∆K15#5-BAC.   
  
C 
A 
Figure 3.1  Deletion of the K15 open reading frame from the KSHV genome.
open reading frame (ORF) was deleted by 
in the context of a bacterial artificial chromosome.  Kanamycin resistance cassettes were 
designed to recombine with three different regions of the K15 ORF.  KSHV
designed to have all but 117 
deleted, while KSHV∆K15#5 retains the first exon and 207
KSHV∆K15 bacterial artificial chromosomes (BAC) were digested with FspI, StuI, or MfeI + 
EcoRI and digested fragments were resolved by agarose gel electrophoresis with ethidium 
bromide staining.  Restriction enzyme sites were gained or lost in the recombination event.  
Changes in digested DNA fragment sizes are designated by arrows.  C)  Deletion of the K15 
ORF and insertion of the kanamycin resistance cassette was confirmed by southern blot of PstI
digested WT KSHV or KSHV∆
the 3’ end of the K15 ORF was designed so that a 1.3
BAC lane, whereas bands of 864
#4, and #5 lanes respectively.  Bands complimentary to the Kanamycin probe were only 
detected in the KSHV∆K15 lanes and not in the WT KSHV lane, as expected.  
KSHV∆K15-BAC and Northern blot analysis were performed by Cyprian Rosetto in the Pari lab 
at the University of Nevada. 
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Figure 3.1 (continued) D, E) K15 expression was investigated at the transcriptional and 
translational levels in KSHV-BJAB cells either uninduced or induced to undergo lytic 
reactivation with phorbol 12-myristate 13-acetate (PMA or TPA).  D)  RNA was isolated from 
WT KSHV or KSHV∆K15-BJAB cells and reverse transcribed.  PCR was performed with primer 
sets that amplify K15 or β-actin.  RNA isolated from uninfected BJAB cells was included as a 
negative control.   E) Lysates from WT KSHV or KSHV∆K15-BJAB cells were subjected to 
SDS-PAGE and transferred to nitrocellulose membranes.  Endogenous K15 expression was 
detected using an antibody raised to a C-terminal K15 peptide.  Lysates from uninfected BJAB 
cells were included as a negative control.  F) The K15 ORF may overlap with the ORF75 
promoter.  To investigate if deletion of the K15 ORF affected expression of the lytic ORF75, 
RNA was isolated from WT KSHV or KSHV∆K15-BJAB cells treated with or without PMA.  
RNA was reverse transcribed into cDNA.  PCR was performed with a primer pair designed to 
amplify the full-length transcript.  RNA isolated from BJAB cells was used as a negative control.  
N = no template control, C = genomic DNA isolated from BCBL-1 cells, as a positive control, M 
= size marker. 
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The smaller fragments are identified with arrows in Figure 3.1B.  Insertion of the KanR 
expression cassette removed a StuI site from the KSHV∆K15-BACs, resulting in the loss of 
3.6 and 6.0 kb fragments in StuI-digested WT KSHV-BAC.  These fragments were replaced 
by 8.9, 9.1 and 9.3 kb fragments in the KSHV∆K15-BACs #3, #4 and #5 respectively.  Loss 
of the 6.0 kb fragment from the mutant KSHV-BACs is highlighted in Figure 3.1B.  Finally, 
digestion of the KSHV-BACs with MfeI + EcoRI resulted in a 4283 bp fragment in the WT 
KSHV-BAC, a 4002 bp fragment in the KSHV∆K15#3-BAC, a 3960 bp fragment in the 
KSHV∆K15#4-BAC, and a 4100 bp fragment in the KSHV∆K15#5-BAC, as depicted in 
Figure 3.1B.   
Finally, to confirm insertion of the KanR expression cassette in the K15 ORF, the 
KSHV∆K15-BAC DNA and WT KSHV-BAC DNA were digested with restriction enzyme PstI, 
subjected to agarose gel electrophoresis and transferred by capillary action to nylon 
membrane.  Membranes were probed with a radiolabeled probe complimentary to an 
undeleted region of the K15 ORF or a radiolabeled probe complimentary to the kanamycin 
resistance gene (Figure 3.1C).   As expected with the probe complimentary to the K15 ORF, 
a 1295 bp band was detected in the WT KSHV-BAC, whereas a band of 864 bp was 
detected in the KSHV∆K15#3-BAC, a band of 944 bp in the KSHV∆K15#4-BAC, and a band 
of 1014 bp in the KSHV∆K15#5-BAC.  No radiolabeled bands were detected in the PstI-
digested WT KSHV-BAC with a probe complimentary to the KanR cassette. A 587 bp band 
was common to all KSHV∆K15-BACs.  In addition, the KanR probe also detected an 864 bp 
band in KSHV∆K15#3-BAC, a 944 bp band in the KSHV∆K15#4-BAC, and a 1014 bp band 
in the KSHV∆K15#5-BAC (Figure 3.1C). 
The WT KSHV and KSHV∆K15#3 BAC DNA (from here on referred to as 
KSHV∆K15-BAC) were then introduced into BJAB cells.  The KSHV-BJAB cells were 
cultured in the presence of hygromycin selection for at least two weeks to obtain a 
population of cells that stably maintained the viral genome, as evidenced by > 95% green 
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fluorescent protein (GFP) expression.  RNA was isolated from the uninduced stable cell 
populations and was subjected to RT-PCR for the viral K15 gene and a cellular β-actin 
gene. Viral K15 transcripts were detected in the WT KSHV-BJAB cells, but not in the 
KSHV∆K15-BJAB cells, whereas β-actin transcripts were amplified from all cultures but not 
a no template control (Figure 3.1D).   Consistent with previous reports, K15 transcription 
increased upon reactivation of lytic replication by phorbol 12-myristate 13-acetate 
(PMA/TPA) in the WT KSHV-BJAB cells.   
Endogenous K15 protein expression was also detected in WT KSHV-BJAB but not 
KSHV∆K15-BJAB cells by western blot with an antibody raised against the C-terminus of 
the K15 protein (Figure 3.1E).   Upon PMA/TPA induction, increased K15 RNA (Fig. 3.1D) 
and protein expression (Fig. 3.1E) was detected in WT KSHV-BJAB cells but remained 
undetectable in the KSHV∆K15-BJAB cells and the untransfected BJAB cells. 
In order to ensure that the deletion of the K15 ORF did not affect the adjacent 
ORF75 gene, we examined ORF75 transcription in the WT KSHV- BJAB cells.  The WT 
KSHV-BJAB and KSHV∆K15-BJAB stable cells were either left uninduced or induced with 
PMA/TPA for 24h. RNA was isolated from both cell lines and RT-PCR was performed with a 
primer set designed to amplify the full-length ORF75 transcript or β-actin as a control 
(Figure 3.1F).   The lytic ORF75 was not expressed either in uninduced WT KSHV-BJAB or 
uninduced KSHV∆K15-BJAB cells, but was expressed by both cell types upon reactivation 
of lytic viral replication by addition of PMA/TPA to the growth medium.   
K15 promotes IL-6 secretion in the context of viral infection 
In order to determine if K15 affects IL-6 expression in the context of viral infection, 
we treated WT KSHV-BJAB stable cells or KSHV∆K15-BJAB stable cells with PMA/TPA or 
a vehicle control to determine if K15 exerts an effect on hIL-6 expression during viral 
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reactivation and during viral latency.  After 24h, we collected conditioned medium from the 
cells and performed RT-PCR to detect IL-6 transcripts (Figure 3.2A) and an ELISA to detect 
IL-6 cytokine secretion (Figure 3.2B).  The IL-6 RNA levels in the uninduced WT KSHV-
BJAB cells were 50% higher than in the uninduced KSHV∆K15-BJAB cells.  Upon 
PMA/TPA reactivation, similar amounts of IL-6 transcripts were obtained in both cell lines 
(Figure 3.2A).  Small amounts of cellular IL-6 (4.6 pg/ml) were secreted by uninduced WT 
KSHV-BJAB cells, while the PMA/TPA induced cells secreted 8.1 pg/ml IL-6.   IL-6 secretion 
from uninduced KSHV∆K15-BJAB cells was below the limit of detection for the assay.  
Following PMA/TPA treatment, IL-6 levels in culture medium from KSHV∆K15-BJAB cells 
did increase to detectable levels (2 pg/ml), but secretion was still impaired as compared to 
the wild-type KSHV-BJAB cells (Figure 3.2B).  Thus, K15 promotes hIL-6 secretion when 
ectopically expressed in B lymphoctes as well as in the context of viral infection.   
 
Figure 3.2  BJAB cells harboring the wild-type KSHV genome exhibit higher IL-6 levels 
than BJAB cells harboring a KSHV genome with the K15 open reading frame deleted.   
Induction of IL-6 expression was examined at the level of transcription (A) and translation (B) in 
KSHV-BJAB cells.  A) Transcription of IL-6 was measured by RT-PCR using cDNA reverse 
transcribed from RNA isolated from WT KSHV or KSHV∆K15-BJAB cells either untreated or 
treated with PMA/TPA.  B) IL-6 secretion was measured in conditioned medium from BJAB 
stable cells harboring either the WT KSHV- BAC or the KSHV∆K15-BAC.  Cells were either 
treated with PMA/TPA or left uninduced. 
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K15 does not affect cellular proliferation or survival of KSHV-BJAB cells 
 Since WT KSHV-BJAB cells secrete more IL-6 than KSHV∆K15-BJAB cells, we 
hypothesized that WT KSHV-BJAB cells might have a growth advantage as compared to 
cells that did not express K15.  5 x 104 WT KSHV-BJAB and KSHV∆K15-BJAB cells were 
seeded at equal density in RPMI-1640 medium supplemented with 2% fetal bovine serum.  
The cells were monitored daily during log growth phase.  Live and dead cells were counted 
using the trypan blue exclusion method to identify any difference in cell growth and/or death.  
WT KSHV-BJAB and KSHV∆K15-BJAB cells had similar growth and death characteristics.  
While the WT KSHV-BJAB cell population doubled 5.9 times (±0.2 times) during the course 
of the 8 day experiment, the KSHV∆K15-BJAB cell population doubled 5.4 times (±0.1 
times) (Figure 3.3A).  Furthermore, both WT KSHV-BJAB and KSHV∆K15-BJAB cells 
remained largely viable (Figure 3.3B). 
 
Figure 3.3  K15 does not affect cell 
growth or survival of BJAB cells.  
Stable cell populations of WT KSHV-
BJAB and KSHV∆K15-BJAB cells 
were seeded at equal density on Day 
0.  Cultures were monitored daily by 
trypan blue exclusion to measure A) 
cell growth and B) cell death.  A)  WT 
KSHV-BJAB cells did not have a 
significant growth advantage over 
KSHV∆K15-BJAB cells.  B)  
KSHV∆K15-BJAB cells may have been 
slightly more prone to cell death.  
However, both cultures remained 
mostly viable during the course of the 
experiment. 
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K15 expression may promote latency in KSHV-BJAB cells 
 To determine if K15 affects viral DNA replication during latency, WT KSHV-BJAB 
and KSHV∆K15-BJAB cell cultures were seeded at equal density as in the cell growth 
experiments.  Cell cultures were allowed to grow for 48h.  Then, total DNA including both 
host chromosomal and viral genomic DNA was isolated from the cells to determine cell-
associated viral load.  Medium was also collected from the cultures to determine cell-free 
viral load.  In each case, viral load was determined by real-time quantitative PCR (QPCR) 
with primers that amplify the viral K49 ORF.  Viral and cellular gene copy numbers were 
determined by comparing cycle threshold values to those derived from serial dilution of a 
K49 or GAPDH expression plasmid of known copy number.  To determine the cell-
associated viral load, viral copy numbers were normalized to GAPDH.  Although cell-
associated viral loads were identical (Figure 3.4A), cell-free viral load was significantly 
higher (5-fold) in KSHV∆K15 cells as compared to WT KSHV-BJAB cells (Figure 3.4B).  
This suggests that a higher percentage of KSHV∆K15-BJAB cells are undergoing 
spontaneous lytic reactivation as compared to WT KSHV-BJAB cells. 
 
 
Figure 3.4  K15 may promote latency in KSHV-BJAB cells.  A)  Total DNA including viral 
genomic DNA and cellular chromosomal DNA was isolated from WT KSHV-BJAB and KSHV∆K15-
BJAB cells.  Real-time QPCR was performed using primers that amplify viral ORF K49 and cellular 
GAPDH to determine the cell-associated viral load.  Equivalent numbers of cell-associated viral 
genomes were detected in both populations.  B)  QPCR was also performed using the K49 primer 
set to assess the presence of viral genomes in conditioned medium of WT KSHV-BJAB and 
KSHV∆K15-BJAB cells.  Cell-free viral loads were five-fold greater in the KSHV∆K15-BJAB cells, 
suggesting that K15 may promote latency in B lymphocytes. 
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Discussion 
The KSHV K15 protein has been detected in primary effusion lymphoma cells and in 
plasmablasts isolated from patients with multicentric Castleman’s disease (49).  K15 has 
been characterized as a latent gene, although K15 expression does increase upon induction 
of lytic replication (4, 11, 19, 49, 63).  In this chapter we have investigated the role of K15 in 
the viral life cycle.  We are the first to report the construction of a KSHV bacterial artificial 
chromosome with the K15 open reading frame (ORF) deleted by homologous 
recombination.  The K15 ORF was replaced by a kanamycin resistance gene expression 
cassette in the mutant KSHV∆K15-BAC.  Restriction enzyme digestion and Northern blot 
analysis suggested that there were no other large deletions or insertions introduced during 
the homologous recombination event.  Introduction of the wild-type and mutant constructs 
into cell lines allows the investigation of K15’s function by reverse genetics.  An added 
advantage to the KSHV-BAC system is that the KSHV-BAC also contains a green 
fluorescent protein (GFP) expression cassette to monitor viral infection (65). 
Stable BJAB B lymphocyte cell lines were created containing the wild-type KSHV-
BAC or the KSHV∆K15-BAC.  After selection with hygromycin B, at least 95% of cells in 
each culture expressed GFP.  K15 mRNA and protein were detected in WT KSHV-BJAB 
cells but not in KSHV∆K15-BJAB cells.  mRNA and protein levels increased in the WT 
KSHV-BJAB cells upon induction of lytic replication, consistent with previous reports that 
expression of K15 is induced by the viral lytic switch protein, RTA.  Substitution of the K15 
ORF by the KanR cassette did not affect expression of the adjacent ORF75 gene product, 
which was detected in both cell cultures after induction of lytic replication.  These results 
were reasonably reassuring that deletion of the K15 ORF by homolgous recombination did 
not introduce any unintended alterations in the viral genome or interfere with adjacent viral 
gene transcription.  Thus, the BAC system was ideal for characterization of K15’s function. 
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Since we had previously determined that ectopic expression of K15 in B 
lymphocytes induces multiple cellular cytokines and most notably IL-6, we first measured IL-
6 expression in WT KSHV-BJAB and KSHV∆K15-BJAB cells.  The importance of the IL-6 
signaling pathway in viral pathogenesis is underscored by the high levels of cellular and viral 
IL-6 expression in KSHV-associated malignancies (1, 13, 23, 36, 39, 41).  Our study 
indicates that K15 can induce cellular IL-6 expression during KSHV latency in B cells.  
During viral latency and PMA/TPA-induced viral reactivation, IL-6 secretion was significantly 
increased in the wild-type KSHV-BJAB cells (4.6 and 8.1 pg/ml respectively) as compared to 
the KSHV∆K15-BJAB cells where IL-6 was absent in uninduced cells and barely detectable 
following induction with PMA/TPA.  The concentration of IL-6 secreted by wild-type KSHV-
BJAB cells is similar to IL-6 secretion by BCBL-1 cells (50), from which the KSHV-bacterial 
artificial chromosome was derived (65).  Low-level IL-6 expression was detected in 
KSHV∆K15-BJAB cells only after PMA/TPA stimulation.  Lytic viral proteins have also been 
shown to induce cellular IL-6 expression and may account for this low-level of expression 
following induction of viral lytic replication.  Alternatively, the IL-6 promoter has TPA-
response elements (TREs).  PMA/TPA activates AP-1 transcription factors that initiate 
transcription after binding to TREs in the promoters of target genes, such as IL-6.  In 
aggregate, these results suggest that the KSHV∆K15-BJAB cells are capable of producing 
IL-6, but that the absence of K15 significantly impairs IL-6 induction in KSHV-positive cells.  
Thus, K15 may contribute to the induction of IL-6 in KSHV-associated malignancies.  
Furthermore, since IL-6 has been shown to promote cell survival, it follows that K15 may 
indirectly stimulate proliferation and survival of the infected cell by upregulating the IL-6 
signaling pathway. 
Cellular IL-6 binds to the IL6 receptor alpha (IL6-Rα)-gp130 complex to initiate 
signaling via the JAK-STAT pathway with anti-apoptotic and proliferative end effects (18, 20, 
21, 27, 28, 30, 31, 57, 58).  Therefore, we queried whether induction of IL-6 expression by 
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the latent K15 protein might stimulate cell growth and division and protect the infected cell 
from programmed cell death.  In order to shed light on the role of K15 in cell growth and 
survival, we examined cell proliferation and cell death in our KSHV-BJAB stable cell lines.  
We noticed minimal differences in cell growth characteristics and in cell death.  In 
retrospect, this finding is not surprising since the BJAB cell line was created by adaptation of 
an EBV-negative Burkitt’s lymphoma to tissue culture, hence the cell line is already 
transformed (33).  Moreover, no appreciable levels of IL-6 are detected in uninfected BJAB 
cell cultures even after PMA/TPA induction (24) (and Nun and Damania, unpublished data), 
suggesting that this B cell line is no longer dependent on IL-6 for proliferation.  This is 
further supported by the observation that IL-6 did not stimulate BJAB proliferation in reduced 
serum conditions (26).  In spite of this, IL-6 transcript and protein levels can be detected 
after introduction of exogenous proteins into BJAB cells (24), demonstrating that the IL-6 
gene is not deleted in BJAB cells but is highly regulated.  Regardless, to determine if K15-
mediated IL-6 secretion provides a survival advantage to infected B cells, the role of K15 in 
survival of primary EBV-negative B cells should be assessed after introduction of the WT 
KSHV-BAC or KSHV∆K15-BAC.    
During viral latency only a small number of genes are expressed.  Thus the functions 
of those genes are presumed to be important for maintenance of the latent viral genome, for 
cell survival and evasion from the immune system, and/or for viral oncogenesis.  Although 
we were unable to define the role of K15 in cell growth and survival, the KSHV-BJAB 
system did allow us to address a corollary change in viral life cycle.  We used real-time 
quantitative PCR to measure latent intracellular and extracellular viral loads in BJAB cells 
harboring the wild type or mutant K15 viral genomes.  Both WT KSHV- and KSHV∆K15-
BJAB cells carried approximately one viral genome per cellular chromosome prior to 
induction with PMA/TPA as determined by real-time QPCR.  Despite that both cell lines 
contained similar viral genome copies per cell, the KSHV∆K15-BJAB cells had 5-fold higher 
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viral genome copies in the supernatant as compared to the WT KSHV-BJAB cells.  This 
suggests that K15 expression might limit spontaneous viral reactivation in the latent cell 
population.  We might have expected that intracellular viral genome copy number would 
also be increased in spontaneously reactivated cell cultures.  However, small differences in 
percentage of cells undergoing lytic reactivation may mask this effect, while cell-free virus 
accumulates in the medium.  Additionally, lytic reactivation culminates in death of the 
infected cell.  Based on the cell proliferation assay, there was a very slight difference in cell 
death in the KSHV∆K15-BJAB cells as compared to the WT KSHV-BJAB cells.  Viral 
genomes may have been released into the supernatant medium upon cell death accounting 
for the large increase in extracellular viral genomes, since we did not differentiate genomes 
incorporated into virions from naked viral genomes in the cell-free supernatant.  
Although we did not specifically examine the role of K15 in the lytic cycle, it has been 
reported by many groups that K15 expression increases during lytic replication in response 
to promoter activation by the viral lytic switch protein, regulator and transcription activator 
(RTA) (4, 11, 19, 48, 63).  Indeed, we have shown here that K15 expression increases 
following PMA/TPA induction in our KSHV-BJAB model system.  The highest levels of K15 
expression are seen 24h after PMA/TPA induction and persist beyond 48h (43, 48).  
Perhaps K15 expression following lytic induction favors a return to viral latency and evasion 
of the immune response.  Future studies should address a possible role of K15 in 
repression of lytic replication and/or virion release following chemical induction in B cells.  A 
potential protective role for K15 via repression of lytic replication should also be examined in 
in vivo studies.  It would also be interesting to investigate a potential effect of IL-6 secretion 
on viral genome replication and the viral life cycle beyond cell survival and proliferation.      
The studies included in this chapter indicate that K15 serves to regulate the cytokine 
environment in infected B cells and plays an important role in the viral life cycle.  Future 
studies will undoubtedly confirm the importance of K15 in modulating the host cell 
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environment.  We propose that K15 may alter the cell environment in such a way that 
supports viral latency and limits lytic replication, thus favoring viral persistence with minimal 
detection by the host organism.   
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Abstract 
Tumors associated with Kaposi’s sarcoma-associated herpesvirus (KSHV) infection include 
Kaposi’s sarcoma, primary effusion lymphoma and multicentric Castleman’s disease.  
Virtually all of the tumor cells in these cancers are latently infected and dependent on the 
virus for survival.  Latent viral proteins maintain the viral genome and are required for 
tumorigenesis.  Current prevention and treatment strategies are limited, because they fail to 
specifically target the latent form of the virus, which can persist for the lifetime of the host.  
Thus, targeting latent viral proteins may prove to be an important therapeutic modality for 
existing tumors as well as in tumor prevention by reducing latent virus load.  Here, we 
describe a novel fluorescence-based screening assay to monitor the maintenance of the 
KSHV genome in B lymphocyte cell lines and to identify compounds that induce its loss, 
resulting in tumor cell death.  
Introduction 
Kaposi’s sarcoma-associated herpesvirus (KSHV), or human herpesvirus-8, is a 
member of the gammaherpesvirus family, distinguished by the ability of its members to 
transform host cells.  KSHV has been linked to multiple types of cancer, including all forms 
of Kaposi’s sarcoma (KS) (1), primary effusion lymphoma (PEL) (5) and the plasmablastic 
variant of multicentric Castleman’s disease (MCD) (40).  These cancers are more prevalent 
in immunodeficient populations, such as transplant patients and HIV-infected individuals 
(18, 28, 38, 40).  In fact, KS is the most frequent AIDS-associated cancer in the US and 
world-wide (27). 
Following primary infection, KSHV establishes latent infection in the host cell, with 
only a small population of cells undergoing spontaneous lytic reactivation (31, 41).  During 
latency, a limited number of viral proteins are expressed, including the latency-associated 
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nuclear antigen (LANA), vFLIP, vCyclin, kaposin and K15 (36, 37).  Each viral latent protein 
plays an important role in viral pathogenesis and KSHV-associated tumorigenesis.  LANA 
plays a pivotal role in maintenance and segregation of the viral genome during latency (2), 
and thus is also essential for cell survival (8).  Maintenance of the viral genome is absolutely 
dependent on the LANA protein, which tethers the latent viral episome to the host cell 
chromosome, ensuring that the viral genome is replicated with the host genome and is not 
diluted out of the expanding population of latently infected cells (9, 16).  If the viral episome 
is lost, LANA and the other latent viral oncogenes are no longer expressed, and the tumor 
cell dies. 
Currently there is neither a cure nor a therapeutic vaccine for KSHV infection.  Highly 
active antiretroviral therapy has reduced the incidence of KSHV-associated tumors in the 
HIV-positive population, yet KS remains the most prevalent AIDS-associated neoplasm, 
even in individuals on long-term therapy (12).  Ganciclovir, which specifically inhibits lytic 
viral replication, has reduced the incidence of KSHV-related tumors in transplant recipients 
(reviewed in (21)).  However, treatment for pre-existing KSHV-associated malignancies 
relies on interferon-alpha administration and systemic chemotherapeutic regimens, 
developed for non-virus-associated cancers, that target DNA replication of all dividing cells 
(reviewed in (46)).  Although clinical trials are assessing new treatment options, a cure 
remains elusive largely due to the lack of compounds that specifically target latent proteins, 
which allow the virus to persist throughout the host’s lifetime.  Recently, Curreli et al. 
reported that high concentrations of glycyrrhizic acid, originally isolated from licorice 
(Glycyrrhiza glabra), could downregulate the expression of LANA in vitro (11).   
Nature continues to be a valuable source for new anti-microbial and anti-cancer 
pharmaceuticals (22, 39).  From 1984-1995, over 65% of new drugs in these medical fields 
were derived directly from natural sources or were synthesized, but modeled after a natural 
product lead compound (10, 29).  Two anticancer chemotherapeutics derived from natural 
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products, Taxol (44) (paclitaxel) and FDA approved analogs of camptothecin (43) (irinotecan 
and topotecan), together represent at least one third of the world-wide market for anti-
neoplastic agents (30).  Indeed, natural products represent a rich reservoir of chemically 
diverse compounds with biological relevance in many disease states (4). 
This report describes the development of a fluorescence-based assay to screen for 
samples that inhibit latent KSHV persistence.  The assay identifies samples that interfere 
with viral genome maintenance during latency irrespective of the specific biochemical 
mechanism, thus multiple targets are screened for simultaneously.  In order to accomplish 
this, a KSHV-GFP recombinant virus (47) was introduced into a KSHV-negative B 
lymphocyte cell line (BJAB) to create a KSHV-BJAB cell line.  KSHV-BJAB cells were 
chosen for two reasons.  First, fluorescence and hence, viral genome maintenance, could 
be monitored over time in live KSHV-BJAB cell cultures.  Samples that interfere with viral 
genome maintenance could be identified by measuring an accelerated reduction in 
fluorescence with respect to a vehicle control since the recombinant viral genome is 
expelled from the dividing cell population.  Second, since the BJAB cell line does not require 
KSHV infection for its survival but can support long-term latent viral persistence (6), using 
KSHV-BJAB cells uniquely allowed the distinction between samples that caused loss of the 
latent viral episome and those that were generally toxic to the host cell.  This was essential, 
because naturally infected PEL cell lines, such as BCBL-1 (34), require viral infection to 
survive, and therefore do not allow a distinction between specific anti-viral and broadly 
cytotoxic compounds, since compounds that induce loss of the virus also lead to cell death.  
As broadly cytotoxic compounds are often associated with multiple side effects resulting 
from non-selective toxicity, the utility of a live cell screen should improve the identification of 
compounds that may exhibit selective antiviral activity in vivo.  In this report, samples that 
proved efficacious in the KSHV-BJAB cell line were also tested in the naturally infected 
BCBL-1 cell line to confirm that loss of the virus corresponded with PEL cell death.  
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In addition to the application described here, this assay can be adapted for use with 
other viruses, such as Epstein-Barr virus, that exist episomally in the host cell.  It can be 
used to screen various collections (ranging from pure compounds to crude extracts) for 
samples that interfere with viral persistence.  In this report, we used this assay to screen a 
small library of plant extracts and identified two that selectively induced loss of KSHV virus 
from infected cells.    
Materials and Methods 
Cells and media.  
The KSHV-negative BJAB lymphoid cell line and the KSHV-positive BCBL-1 cell line were 
obtained from ATCC.  BJAB cells were maintained in RPMI-1640 medium supplemented 
with 10 % FBS, 100 U/mL penicillin and 100 µg/mL streptomycin.  BCBL-1 cells were 
maintained in the same medium additionally supplemented with 1mM NaHCO3 (Gibco) and 
0.05 mM 2-mercaptoethanol (Sigma).  The BJAB-derived cell line, KSHV-BJAB, was 
created by nucleofection of KSHV-negative BJAB cells with the KSHV bacterial artificial 
chromosome containing a hygromycin antibiotic resistance marker and the green 
fluorescent protein expression cassette (47).  Cells containing the KSHV genome were 
selected for a minimum of two weeks in RPMI-1640 medium supplemented with 10% fetal 
bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin and 0.2 mg/ml hygromycin B.  
Unless otherwise noted, growth media and supplements were obtained from Cellgro.  
Plant collection and processing.   
Plant samples were collected in Manus Island, Papua New Guinea, in 2003 under a UIC-
UPNG Memorandum of Agreement 2003-2008 and approval of the PNG 
BioNET/Department of Environment and Conservation dated May 21, 2003.  A set of 
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voucher herbarium specimens has been deposited at both the Herbarium of the University 
of Papua New Guinea, Port Moresby and the John G. Searle Herbarium, Field Museum, 
Chicago.  Taxonomic identifications were performed by one of the authors (PP) and 
confirmed by staff of the Lae Herbarium, Papua New Guinea and by one of the authors 
(DDS).  The collection and processing strategies for these understudied plant specimens 
from tropical rainforests has been recently reviewed (20).  Briefly, a pilot sample (~20 g, dry 
weight) was extracted with 9:1 MeOH:H2O. The resultant extract was defatted with hexanes, 
and the residual material was partitioned between 4:1:5 CHCl3:MeOH:H2O.  Importantly, the 
organic-soluble fraction was washed with 1% NaCl to remove tannins (42), which are known 
to interfere with some biological assays.  The de-tannified organic fraction of each sample 
was tested for biological activity.   
Fluorescence assay.   
100,000 cells of each B lymphocyte cell line were suspended in RPMI-1640 medium 
(Cellgro) supplemented with 2% fetal bovine serum (Cellgro), 100 U/mL penicillin and 100 
µg/mL streptomycin (Cellgro) and were placed in subsequent wells of a 24-well plate.  
Hygromycin selection was withdrawn from KSHV-BJAB cells to prevent competition with 
screened samples.  In the case of plant samples, the de-tannifed organic fraction or an 
equal volume of dimethyl sulfoxide (DMSO) was added to the growth medium at a final 
protein concentration of 2 µg/ml.  The pure compound and positive control, glycyrrhizic acid 
(Sigma) dissolved in 5% EtOH at a pH of 7.2, was diluted to 2 mM (1680µg/ml), 3 mM 
(2520µg/ml), 4 mM (3360µg/ml), and 6 mM (5040µg/ml) in RPMI-1640 (Cellgro) 
supplemented with 2% fetal bovine serum (Cellgro), 100 U/mL penicillin and 100 µg/mL 
streptomycin (Cellgro).  Half of the culture medium was siphoned from each well and 
replenished with fresh medium and identical concentrations of glycyrrhizic acid or plant 
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sample (2 µg/mL) twice each week without passaging the cells.  Mean fluorescence of the 
live cultures, incubated with test or control samples, was measured using a Fluostar 
fluorimeter every two to three days.  Optimal parameters for detection were excitation 
wavelength 485 nm, emission wavelength of 510 nm and orbital well scanning.  
Real Time QPCR.   
Total DNA (including cellular genomic and viral DNA) was isolated from cells after five 
weeks incubation with test samples or vehicle controls using the Promega Wizard Genomic 
DNA Kit.  Real Time QPCR was performed with primers specific for the cellular U6 gene 
and the viral vGPCR gene as previously described (13).   Using this method to analyze 
BCBL-1 cells serially diluted in a suspension of uninfected BJAB cells, we were able to 
detect as few as 1 infected cell in 10,000 (Supplementary Figure 4.1) with 95% efficiency.  
In the BJAB and BCBL-1 cells, the cytotoxicity of the plant samples was assessed using the 
equation 1.9-∆CT(U6) to normalize the data to the DMSO control.  Results were expressed as 
% viability.  In KSHV-BJAB cells, selective inhibition of the virus was assessed by first 
normalizing the cellular and viral data to the DMSO control, then determining the ratio, or 
selectivity index SI = 1.9[∆CT(U6)-∆CT(vGPCR)], of viral toxicity versus cellular toxicity. 
  
Supplementary Figure 4.1 Determination 
of the efficiency of the real time QPCR 
assay and limit of detection.  Naturally 
infected BCBL-1 cells were serially diluted 
into a suspension of uninfected BJAB cells.  
Real time QPCR was performed using viral 
(vGPCR) and cellular (U6) primer sets.  
The cycle threshold for the viral primer set 
was plotted against the dilution.  The slope 
of the line was 3.6, corresponding to 95% 
efficiency based on the equation 10(1/m), 
where m is the slope.  Finally, the viral 
QPCR yielded a detectable signal with 1 
infected cell in 10,000 but not for 1 infected 
cell in 100,000, thus establishing our limit 
of detection at 1 infected cell in 10,000.   
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Immunofluorescence.   
After one week, approximately 100,000 BCBL-1 cells cultured with plant extract or a DMSO 
vehicle control were spotted on slides.  Cells were fixed and permeabilized in pre-cooled 
acetone at -20°C for 15 min.  Slides were washed in PBS.  Normal goat serum (10% in 
PBS) was used to block non-specific antibody binding.  The slides were incubated for 1 h at 
room temperature with anti-KSHV ORF-73 (LANA) rat monoclonal antibody (1:100, 
Advanced Biotechnologies).  Slides were washed twice in PBS, then incubated for 30 
minutes at room temperature with anti-rat TRITC-conjugated IgG (1:100, Sigma).  Slides 
were washed twice in PBS and once in distilled water and allowed to dry.  Vectashield was 
applied to preserve fluorescence.  
Results 
Development of the screening assay. 
The KSHV-BJAB cell line was established by introducing the complete KSHV 
genome in the context of a bacterial artificial chromosome (KSHV-BAC) (47) into uninfected 
B lymphocytes (BJAB).  The KSHV-BAC contains both a mammalian hygromycin antibiotic 
resistance marker and the green fluorescent protein (GFP) expression cassette.  
Transfection of BAC viral DNA was previously shown to result in fully replication-competent 
virus and circumvented any receptor or post-entry blocks that may limit the efficiency of 
natural infection of B cells with KSHV (6, 23, 47).  KSHV-BJAB cells were selected in 0.2 
mg/ml hygromycin B in order to achieve a stable KSHV-positive cell line.   
KSHV-BJAB cells harboring the KSHV-BAC express GFP, thus providing a means to 
screen for samples that interfere with latent viral genome maintenance.  Inhibition of viral 
genome maintenance results in loss of fluorescence as the viral episome is lost from the 
dividing cell population.  Since KSHV episome loss occurs at cell division (17), multiple cell 
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division cycles must take place before a significant loss of fluorescence can be observed.  
The design as a multi-cycle assay also increased the sensitivity and allowed us to prioritize 
potential lead samples based on their effectiveness.   
To screen for samples with activity against latent KSHV infection, hygromycin 
selection was removed from the KSHV-BJAB cells to prevent competition with the screened 
samples.  Cells were incubated with test and control samples for five weeks.  Culture 
medium and samples were replenished twice each week without passaging the cells.  
Primary screening of samples was achieved by measuring the mean fluorescence of the 
GFP+ KSHV-BJAB cells every two to three days (Figure 4.1A).  Mean fluorescence was 
plotted over time to identify samples that accelerated loss of fluorescence in the KSHV-
BJAB cell line with respect to a vehicle control.  The uninfected BJAB cell line served as an 
additional control against broad-spectrum cytotoxic effects of the tested samples.  A 
naturally infected KSHV-positive PEL cell line, BCBL-1 (34), was also included to confirm 
the antiviral effects of lead samples by real-time QPCR  and indirect immunofluorescence 
assays for LANA (Figure 4.1A). 
Validation of the screening assay 
To validate the assay, a known inhibitor of KSHV latency, glycyrrhizic acid (GA), was 
tested.  At 3 mM, GA has been shown to downregulate expression of the latency-associated 
nuclear antigen (LANA) of KSHV (11). KSHV-BJAB cells were incubated with 2-6 mM GA or 
an ethanol control (final ethanol concentration 0.6%).  Culture medium was replaced twice 
each week with fresh medium plus GA without passaging the cells.  In the ethanol control or 
2-4 mM GA-treated KSHV-BJAB cultures, fluorescence increased from day 1 to day 7 as 
KSHV-BJAB cells proliferated.  After day 7, fluorescence leveled off in the ethanol control 
cultures, whereas cells incubated with GA showed a dose-dependent decrease in mean  
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fluorescence (Figure 4.1B).  At 6 mM, GA inhibited the initial proliferative burst of KSHV-
BJAB cells, most likely due to broad cytotoxicity.  By day 18, the majority of KSHV-BJAB 
cells incubated with 2 mM GA no longer exhibited green fluorescence, but remained viable 
(Figure 4.1C, middle panel), in contrast to the gross cytotoxicity observed at 6 mM GA 
(Figure 4.1C, right panel).  On day 18, uninfected BJAB cells also remained viable at 2 mM 
GA, but lost viability at 6 mM GA (data not shown).  
       
Figure 4.1 Validation of the assay.  A) Cells from three B lymphocyte cell lines (BJAB, KSHV-
BJAB, BCBL-1) are incubated in RPMI media containing test or control samples.  Samples are 
initially screened for loss of fluorescence in the KSHV-BJAB cells, suggestive of loss of virus.  To 
verify loss of virus from the cells, additional assays are performed including real time PCR viral 
load assays and immunofluorescence assays for LANA.  B) Incubation of KSHV-BJAB cells with a 
known inhibitor of KSHV latency, glycyrrhizic acid, leads to a dose-dependent decrease in mean 
fluorescence as compared to an ethanol control.  C)  Digital images of the KSHV-BJAB cells 
incubated with glycyrrhizic acid (2 mM and 6 mM) or an ethanol control.  The top image of each 
pair represents the fluorescence.  The bottom image of each pair represents the merged 
fluorescent and bright field images.  D)  Real time QPCR using primer sets to amplify viral 
(vGPCR) and cellular (U6) regions of DNA isolated from BCBL-1 cells incubated with glycyrrhizic 
acid or an ethanol control.  Dose-dependent increases in the cycle threshold for viral (open circles) 
and cellular (black diamonds) template as compared to the EtOH control were evident.   
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The antiviral effect of GA was verified by viral load assays.  Total cellular and viral 
genomic DNA was isolated from BCBL-1 cells or KSHV-BJAB cells incubated with GA or an 
ethanol control for seven days.  As expected, the cycle threshold for both the cellular (U6) 
and viral (vGPCR) primer sets increased in a dose-dependent manner indicating a 
simultaneous reduction of both viral and cellular DNA (Figure 4.1D).  This was expected as 
GA interfered with viral latency, leading to loss of viral DNA and, since the KSHV genome is 
required for BCBL-1 cell survival, a loss of cellular DNA as well.  GA selectively inhibited the 
virus in KSHV-BJAB cells, which do not depend on the virus for survival, with reductions in 
viral load on average 17 times greater than reductions in cellular DNA (data not shown).  
These results served to validate our assay.  However, cumulative cytotoxic effects became 
evident in all GA cultures, including the uninfected BJAB cultures, after 18 days of treatment 
(data not shown).  Therefore, despite its initial selective antiviral effect, GA is unlikely to be a 
good drug candidate given its cumulative broad cytotoxicity.  Moreover, the relatively high 
concentration required for a positive response in vitro could be difficult to achieve in vivo. 
Identification of antiviral plant extracts 
Having validated the assay, a screening set of 81 plant extracts was tested for anti-
KSHV activity.  All extracts were dissolved in dimethyl sulfoxide (DMSO) and were tested at 
a final concentration of 2 µg/ml in RPMI.  An equal volume of DMSO served as a vehicle 
control.  Culture medium was replaced twice each week with fresh medium plus plant 
extract, without passaging the cells.  Mean fluorescence measurements from KSHV-BJAB 
cultures were taken every 2-3 days.  Fluorescence from KSHV-BJAB cells treated with 
DMSO plateaued within one week as the cells achieved equilibrium.  Sixty-two extracts 
exhibited insignificant changes in fluorescence of KSHV-BJAB cultures with respect to the 
DMSO control.  Eight extracts marginally reduced fluorescence, while six extracts 
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consistently decreased fluorescence 
by at least 50% of the DMSO control 
without apparent cytotoxicity 
(Supplementary Table 4.1).  Four 
extracts exhibited acute and one 
delayed (cumulative) cytotoxic effects 
irrespective of the cell’s infection 
status. 
 
 
Extracts that decreased fluorescence 
Figure 4.2 displays the mean fluorescence graphs of six extracts (A05810, A05830, 
A05831, A05853, A05898 and A05901) that consistently decreased fluorescence by ≥50% 
of the DMSO control in four separate trials.  Two distinct trends were observed within this 
group of six extracts.  Fluorescence of KSHV-BJAB cells incubated with extracts A05810, 
A05830, and A05898 (Figure 4.2A) peaked within 7 days, then decreased steadily until 
achieving a new plateau level of fluorescence at least 50% less than the DMSO control, but 
still above background.  Fluorescence from KSHV-BJAB cells incubated with extracts 
A05831, A05853 and A05901 (Figure 4.2B) peaked within 7 days, then steadily declined 
throughout the experiment.   
Figure 4.3 displays digital images of KSHV-BJAB cells after 20 days incubation with 
the six aforementioned extracts and the DMSO control.  Roughly equivalent numbers of 
cells were present in each field.  However, the number of GFP+ cells was reduced ≥50% by 
each of the extracts as compared to the DMSO control.  No visually apparent cytotoxic 
effects of these extracts were evident at day 20.  Furthermore, these extracts were 
 Supplementary Table 4.1  Summary of results 
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assessed at day 14 in uninfected BJAB cells (Supp Figure 4.2A) and in three unrelated 
cancer cell lines (Supplementary Figure 4.2B) and were found to have limited cytotoxicity in 
these assays.  These six extracts that repeatedly decreased fluorescence of KSHV-BJAB 
cells may interfere with episomal maintenance and were chosen for further analyses.     
  
 
 
Figure 4.2  Initial screening for 
antiviral activity is based on loss of 
fluorescence. Mean fluorescence of 
live B lymphocyte cultures incubated 
with potential antiviral compounds is 
measured every two to three days for 
five weeks.  A) Extracts A05810 (grey 
circles), A05830 (gray triangles) and 
A05898 (black crosses) caused 
accelerated loss of mean fluorescence 
in KSHV-BJAB cultures as compared 
to the DMSO control (black diamonds), 
eventually establishing a new plateau 
level of fluorescence ≥50%  less than 
the DMSO control.  B) After incubation 
with extracts A05831 (grey boxes), 
A05853 (black crosses) and A05901 
(grey triangles) fluorescence declined 
steadily and without leveling off, 
suggesting continuous reduction of the 
viral load.   
  
Figure 4.3 Microscopic evaluation of 
KSHV-BJAB cells incubated with 
potentially antiviral plant extracts.  
Digital images of KSHV-BJAB cells 
incubated with representative plant 
extracts that exhibited an accelerated 
loss of fluorescence as compared to a 
DMSO control, suggesting loss of the 
viral genome.  The left image in each 
sub-panel represents the fluorescence.  
The right image in each sub-panel 
represents the merged fluorescent and 
bright field images.  A) Extracts A05810, 
A05830 and A05898 which achieved a 
new plateau level of fluorescence, as 
compared to DMSO.  B) Digital images 
of KSHV-BJAB cells incubated with 
extracts A05831, A05853 and A05901 
which steadily reduced fluorescence as 
compared to the DMSO control.   
  117
Cytotoxic extracts 
In contrast to the extracts that showed a consistent decrease in fluorescence without 
visually apparent cytotoxicity, four extracts, as represented by extract A05854 in Figure 4.4, 
were acutely and uniformly cytotoxic to all three B lymphocyte cell lines tested regardless of 
their infection status.  Additionally, one extract A05814 was found to have cumulative non-
specific cytotoxic effects.  As before, fluorescence from DMSO-treated KSHV-BJAB cells 
increased sharply as cells proliferated, whereas the fluorescence of KSHV-BJAB cells 
incubated with the acutely cytotoxic extract A05854 failed to increase at all and quickly 
achieved baseline levels (Figure 4.4A).  Extract A05814 initially permitted cell proliferation 
concomitant with escalating fluorescence measurements (Figure 4.4A).  However, by day 
14, fluorescence had plummeted to near-background levels.  Whereas the cytotoxicity of 
extract A05854 was unmistakable (Figure 4.4B) at day 20, with only few apoptotic cells 
present, many more cells were present in the A05814 culture (Figure 4.4B) with apoptotic 
changes just becoming visually apparent at this time point.  Key to the distinction and 
 
Supplementary Figure 4.2  Assessment of the toxicity of plant extracts.  A)  Uninfected BJAB 
cells were incubated with plant extracts (2µg/ml) for 14 days, with growth medium and extract 
replacement twice each week.  Cell viability was assessed by the trypan blue exclusion method, 
where cells not incorporating the dye are scored as viable.  Results are normalized to the DMSO 
control.  B)  Three unrelated cancer cell lines (MCF7-wtk, H460 and SF268) were incubated with 
plant extracts (2µg/ml) for three days.  Cells were fixed and stained with a sulforhodamine B dye.  
Toxicity was assessed by detecting the amount of incorporated sulforhodamine B dye, correlating 
to the overall biomass. Figure 4.2B was generated by Yuka Nakanishi. 
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subsequent exclusion of these cytotoxic extracts from further analyses was their non-
selective toxicity to uninfected BJAB and infected BCBL-1 cells alike (data not shown).  
Thus, inclusion of uninfected BJAB cultures in this assay distinguishes generally cytotoxic 
samples from those that are selectively active against KSHV-infected cells and allows us to 
separate specific antiviral activity in our samples from acute and delayed cytotoxic activity.     
Confirmation of antiviral activity by real time quantitative PCR. 
The six extracts (A05810, A05830, A05831, A05853, A05898, A05901 from Figures 
4.2 and 4.3) that decreased fluorescence with respect to the DMSO control in the initial 
fluorescence-based screen were selected for further study.  After incubation with test or 
control samples for five weeks, viral genomic and host chromosomal DNA was isolated from 
BJAB, KSHV-BJAB and BCBL-1 cells.  Each culture began with an identical number of cells 
and was not split during the course of the experiment.  The isolated DNA was resuspended 
in the same volume of buffer, and an equal volume of the isolated DNA was used as 
 
Figure 4.4 Five extracts exhibit cytotoxicity to all three B lymphocyte cell lines.  A) Mean 
fluorescence graph representative of acute and delayed cytotoxic samples, A05854 (circles) and 
A05814 (squares) respectively.  B) Digital images of KSHV-BJAB cells incubated with acutely 
cytotoxic sample A05854 or delayed cytotoxic sample A05814.  The images on the left represents 
the fluorescence, on the right the merged fluorescent and bright field images.  
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template for real time quantitative polymerase chain reactions (QPCR) with viral (vGPCR) 
and cellular (U6) primer sets.  Thus, any increases in cycle threshold (CT) for the cellular 
primer set were likely due to cytotoxic effects of the extract, while changes in the viral CT 
were due to changes in the cell-associated viral load.  After normalizing the raw data to the 
DMSO control, either toxicity in BJAB and BCBL-1 cultures or selectivity in KSHV-BJAB 
cultures was ascertained.  
As expected, the non-template control yielded no signal with either primer set after 
40 cycles.  Likewise the cycle threshold (CT) for the viral primer set in uninfected BJAB cells 
was 40 indicating the absence of viral DNA, whereas the cellular primers (directed against 
the U6 gene) gave a consistent signal (mean CT = 22 ± 1, across the six extracts) similar to 
the DMSO control (CT = 21 ± 1).  Although BJAB cultures remained at least 80% viable at 
day 14 as measured by trypan blue exclusion (Supplementary Figure 4.2A), cytotoxic 
effects became apparent by QPCR at 5 weeks (Figure 4.5A).  BJAB cells treated with 
extracts A05830 and A05831 remained viable (109% and 89% viable respectively, as 
compared to the DMSO control).  Extracts A05810 and A05898 reduced viability by ~50%, 
while extracts A05853 and A05901 reduced viability by greater than 80% compared to the 
DMSO control.   
Next, naturally infected BCBL-1 B lymphoma cells were evaluated.  Each cell 
contains approximately 70 copies of the KSHV episome (25) and its maintenance is vital for 
BCBL-1 survival.  If all viral genomes are lost, the cell dies.  Given the interdependence of 
viral genome maintenance and cell survival in BCBL-1 cells, we analyzed only cytotoxicity of 
the extracts in BCBL-1 cells compared to the DMSO control (Figure 4.5B).  Two of the six 
extracts—A05831 and A05853—were toxic to BCBL-1 cells, reducing viability to 46% and 
2% respectively.  These extracts exhibited expectable increases in both viral and cellular CT 
compared to DMSO (Supplementary Table 4.1).   
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Finally, selectivity of each extract was assessed in KSHV-BJAB cells (Figure 4.5C), 
representing the key innovation of this report since non-specific cytotoxic effects can be 
uncoupled from changes in viral load as KSHV-BJAB cells do not require the virus for 
survival.  Here, the KSHV-specific primers (directed against the vGPCR gene) detected 
drastic changes in KSHV viral DNA resulting in CT values ranging from 28 ± 1 to 39 ± 1 in 
extract-treated cells and 25 ± 1 in DMSO-treated cells, while the cellular DNA (U6 gene) 
remained largely unchanged (mean CT = 22 ± 1 across six extracts, CT = 20 ± 1 in DMSO-
treated cells).  Changes in cellular and viral genomic DNA were first individually normalized 
to DMSO-treated cells.  The selectivity index of each extract was then determined by the 
ratio of viral DNA reduction to host DNA reduction i.e. cytotoxic effects.  Three extracts—
A05831, A05853 and A05901—were highly selective as indicated by selectivity indexes 
 
 
Figure 4.5  Real time QPCR allows potential 
hits to be stratified based on selectivity 
and specificity.  Real time QPCR was 
performed using viral (vGPCR) and cellular 
(U6) primer sets.  For uninfected BJAB (A) 
and naturally infected BCBL-1 cells (B), cell 
viability of extract-treated cells was normalized 
to the DMSO control using the equation: 1.9-
∆CT (U6)
.   C) Cellular and viral DNA in extract-
treated KSHV-BJAB cells were first 
normalized to DMSO-treated KSHV-BJAB 
cells.  Then selectivity index was calculated as 
the ratio of changes in viral DNA to changes in 
cellular DNA.   
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greater than 10, indicating that extract-mediated reductions in viral DNA were 232, 13 and 
152 times greater than reductions in KSHV-BJAB cellular DNA, respectively.   
Taken together the information gleaned from each QPCR experiment was used to 
prioritize samples by the selectivity of their antiviral activity and specificity of their cytotoxic 
effects.  Specifically, extracts that exhibit (i) high selectivity (selectivity index >10 in KSHV-
BJAB cells), (ii) large reductions in BCBL-1 viability (>50%), and (iii) minimal cytotoxic 
effects in BJAB cells would receive higher priority in subsequent analyses.  Of the three 
highly selective extracts we identified, only extracts A05831 and A05853 were toxic to 
BCBL-1 cells, resulting in 54% and 98% reductions in BCBL-1 viability respectively.  While 
extract A05831 was mildly toxic to uninfected BJAB cells (11% reduction in cell viability), 
A05853 was significantly toxic (84% reduction in cell viability) and may require further 
refinement to achieve priority status.  Nonetheless, the fluorescence-based screening assay 
and the QPCR data suggest that extract A05831 and A05853 selectively interfere with viral 
genome maintenance and were chosen for further study as described below.  However, it 
should be noted that, of all the extracts tested, extract A05831 was most selective for viral 
genome loss with minimal cytotoxicity in BJAB cells.   
Assessing LANA expression by immunofluorescence.    
We used an indirect immunofluorescence assay against KSHV latency-associated 
nuclear antigen (LANA) as a first step toward elucidating the antiviral mechanism(s) behind 
extracts A05831 and A05853.  BCBL-1 cells were incubated with plant extracts for seven 
days, then stained with an antibody directed against LANA (anti-KSHV ORF 73) followed by 
fluorophore-conjugated anti-idiotypic immunoglobulins.  Cells incubated with either the 
DMSO control (Figure 4.6A) or extract A05807 (Figure 4.6B) that showed no antiviral effect 
in the screening assays, displayed characteristic speckled nuclear staining.  In BCBL-1 cells  
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that were incubated with extract A05831 or A05853 (Figure 4.6C and 4.6D respectively), 
anti-LANA immunofluorescent staining was decreased to near background levels, indicating 
that loss of viral genome correlated with loss of LANA expression.  
Discussion 
Eradicating latently infected cells represents the ultimate goal in therapy of KSHV-
associated malignancies, where loss of the viral episome expectedly leads to tumor cell 
death.  Currently, treatment of KS, PEL and MCD typically includes chemotherapeutic 
agents that target all replicating cells, failing to distinguish between virally infected and 
uninfected cells.  Such regimens are associated with severe side effects, including 
myelotoxicity and pancytopenia, which can become life-threatening in an already 
immunocompromised population.  Since KSHV infection remains in a latent state in the 
majority of infected tumor cells, drugs that target latent viral proteins may be more effective 
 
Figure 4.6 Indirect immunofluorescence assays for LANA investigate possible mechanisms 
of interference with viral genome maintenance.  BCBL-1 cells incubated with plant extract or a 
DMSO control were spotted on slides and fixed with pre-cooled acetone.  Incubations with anti-
KSHV ORF73 (LANA) monoclonal antibody followed by TRITC-conjugated anti-rat IgG were used 
to detect the presence of LANA.  Images on the left of each panel represent the bright field image.  
Images on the right represent the fluorescent staining of the KSHV LANA.  A) DMSO control  B) 
Extract A05807  C) Extract A05831  D) Extract A05853 
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than current regimens at both preventing and treating disease and may have an added 
benefit of fewer side effects. 
This report describes an assay designed to identify samples that induce viral 
episome loss, irrespective of the specific mechanism, and without generalized cytotoxicity.  
The design hinges on a two-step screen.  The first step identifies samples that cause loss of 
the latent virus in a cell line (KSHV-BJAB) that does not depend on the virus for viability.  
The second step validates those hits in a cell line (BCBL-1) that does depend on the virus 
for survival.   
The initial screening step employs a B lymphocyte cell line (KSHV-BJAB) carrying 
the KSHV-BAC and expressing green fluorescent protein.  KSHV-BJAB cells are incubated 
in medium containing test samples and are monitored for loss of fluorescence (i.e. loss of 
the viral episome).  Seven percent of 81 screened plant extracts consistently reduced 
fluorescence ≥ 50% in KSHV-BJAB cells as compared to a DMSO control.  An additional 
6% of the extracts were cytotoxic to all B lymphocyte cell lines tested, regardless of their 
KSHV infection status.  Eighty-seven percent had no significant effect (data not shown).  
Since non-specific promoter silencing could diminish fluorescence in KSHV-BJAB 
cells, virus-specific effects were verified by real time QPCR for the viral genome.  Using 
primer sets for both a viral (vGPCR) and a cellular (U6) gene and DNA templates isolated 
from BJAB, KSHV-BJAB or a PEL cell line, BCBL-1, after incubation with the test samples, 
cytotoxicity and selectivity of each extract were assessed.  Six extracts, identified as 
potential hits ( ≥ 50% reduction of fluorescence) in the first screening step, were tested.  
Extracts A05831 and A05853 demonstrated selective activity against latent virus, as the 
viral episome was lost from a model infection (KSHV-BJAB) at least 10 times more 
efficiently than host chromosomal DNA (corresponding to cell death).  Furthermore, both 
extracts resulted in at least a 50% reduction in cell viability from naturally-infected tumor 
cells (BCBL-1), as compared to a DMSO control.  Extract A05831 receives higher priority for 
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further study since it is relatively non-toxic in uninfected BJAB cells, while extract A05853 
may prove too non-selectively toxic in its unrefined state.  
In principle, compounds that interfere with viral genome maintenance may target 
cellular or viral proteins required to maintain latency.  Samples exerting their effects by 
targeting viral proteins are preferred, since a specific antiviral effect may be less toxic to 
other highly replicating cells and, presumably, would have fewer side effects than currently 
available chemotherapeutics.  KSHV latency-associated nuclear antigen (LANA) is a likely 
viral target for antiviral samples, since it is essential for KSHV genome maintenance.  In a 
complex with multiple cellular proteins (3, 14, 15, 24, 26, 32, 33), LANA tethers the viral 
genome to the cellular chromosome, ensuring that the two are replicated coincidentally and 
segregated equally to each daughter cell.  Samples that target LANA may accomplish their 
antiviral effect by one or more means, including: (i) transcriptional downregulation, (ii) 
degradation or post-translational modification, (iii) sequestration outside the nucleus, (iv) 
interference with binding to the host chromosome or the viral genome, or (v) similarly 
targeting cellular proteins that complex with LANA.  Additionally, other viral latent proteins 
may also be involved in viral genome maintenance and may also be targeted.     
To explore the mechanism(s) by which extracts A05831 and A05853 propel 
episomal loss, a LANA immunofluorescence assay was performed on BCBL-1 cells 
incubated with the two lead extracts, identified by the initial fluorescence-based screening 
step and verified by QPCR.  Both extracts resulted in near background levels of LANA 
immunofluorescent staining.  Thus, these plant extracts may contain one or more 
compounds that downregulate transcription of LANA, accelerate its degradation, or cause 
post-translational modifications that render it undetectable by this antibody.  Therefore, 
extracts A05831 and A05853 are prime candidates for further experimentation.  Since each 
extract likely contains hundreds of compounds, future studies will employ a bioactivity-
directed fractionation strategy to purify and identify the antiviral constituent(s).   
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Loss of fluorescence mediated by culturing KSHV-BJAB cells with antiviral samples 
is dependent on two things:  loss of the KSHV-BAC, which contains the GFP gene and 
degradation of GFP that is made prior to loss of the gene.  GFP has a reportedly long half 
life, ranging from 26 to 80 hours in eukaryotic cells (7, 19, 35), which contributed to the 
length of the initial screen, which was further extended to five weeks in order to assess 
cumulative cytotoxicity.  Analysis of the data, however, showed that the most potent 
inhibitors already displayed a significant effect by day 20 and the second screening step 
allowed for earlier detection of cumulative cytotoxic effects.   
In modern medicine many highly effective therapeutic agents, such as camptothecin 
and Taxol/paclitaxel, were first isolated from plant extracts and have revealed novel targets 
and mechanisms for antitumor drug action.  While certain herbal extracts were recently 
found to reactivate KSHV (45), the novel assay described in this report identifies plants as a 
rich source for antiviral compounds that may cure KSHV infection by interfering with latent 
viral episome maintenance.  Although a relatively small sample set was tested, the results 
are representative of the discovery potential for samples with therapeutic promise, as an 
overall hit rate of 2% is consistent with other natural product screens, where hit rates 
typically range from 0.5 to 5%, regardless of the biological target.  Indeed, small molecule 
libraries derived from plant or other natural product sources may prove to be repositories for 
antiviral agents with varied targets and activities against a breadth of currently incurable 
viral infections.   
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Conclusions 
Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL), and multicentric 
Castleman’s disease (MCD) are three neoplastic diseases associated with infection of 
malignant cells by the Kaposi’s sarcoma-associated herpesvirus (KSHV) (14, 15, 59, 74).   
In each neoplasia, the virus persists in a latent state in the majority of infected endothelial 
or B lymphocyte cells.  During latency, only a few viral genes are expressed that are 
responsible for maintaining the viral genome, stimulating cell survival, preventing apoptosis, 
and evading the host immune response (41, 65, 71, 72).  Currently, there are no known 
antiviral agents that specifically target the latent phase of the herpesvirus life cycle.  
Antiviral agents that disrupt lytic replication may limit viral spread, but their effects do not 
extend to a cure (38).  Thus, therapies used to treat the three KSHV-associated 
malignancies rely on radiation therapy and conventional chemotherapeutic agents.  These 
strategies target all proliferating cells and thus are associated with severe side effects.   
With this in mind, the main goals of this dissertation project were 1) to investigate the role 
of the viral K15 protein as a potential future target for new antiviral therapies in KSHV-
infected B lymphocytes, and 2) to identify new antiviral agents with activity against latent 
viral infection. 
Antiviral agents that disrupt viral latency may provide the elusive cure for KSHV 
infection and, therefore, also KSHV-associated malignancies by eradicating the oncogenic 
stimulus.  The antiviral “wonder drug” would specifically target cells infected with KSHV, 
and would thus be nontoxic to uninfected cells.  Ideally, the drug would selectively inhibit 
viral gene products that are expressed during latency, either by steric inhibition, by 
selectively stimulating viral protein degradation, or by modification of the viral protein to an 
inactive form.  In addition to targeting viral proteins, interference with signal transduction 
pathways that are specifically deregulated in cancer cells has proven to be an effective 
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strategy for some types of cancer.  For instance, in chronic myelogenous leukemia, the 
constitutively active kinase resulting from bcr-abl fusion has been successfully targeted by 
imatinib and dasatinib, achieving high remission rates (24, 53).  Likewise, understanding 
the signaling properties of viral proteins could help identify new dysregulated cellular 
targets for treatment of KSHV-associated diseases. 
Two methods have been commonly used in drug discovery.  Classically, drugs have 
been discovered by screening known compounds for a desired effect without regard to the 
chemical composition of the drug or the target (6).  In Chapter 4 of this thesis we describe 
an unbiased screening assay that we devised to identify antiviral drugs that are toxic to 
KSHV-infected cells.  More recently, drug discovery has relied on tailor-made chemical or 
biological inhibitors, designed with a specific “druggable” target already in mind (6).    A 
druggable target is one that is likely to be inhibited by an orally bioavailable pharmaceutical 
compound or by a biological inhibitor, such as an antibody (36, 70).  Although defining a 
target’s druggability may be difficult, properties to consider include the tissue distribution 
and subcellular localization of the target.  Proteins located at the cell membrane, e.g. 
epidermal growth factor receptor, or proteins involved in signal transduction, such as 
cellular kinases, have proven to be good druggable targets (36).  Considering the limited 
subset of viral proteins expressed during KSHV latency, we propose the viral K15 protein 
as a promising new target.   
K15 is expressed in B lymphocytes and epithelial cells latently infected with KSHV 
(9, 19, 31, 73).  It is a membrane protein located at the cell surface, and thus would be 
more easily accessible to a small molecule or biological inhibitor than an intracellular viral 
protein.  Furthermore, embedded in the cytoplasmic tail of all K15 isoforms are multiple 
highly conserved signaling motifs (8, 31).  K15 reportedly activates various signal 
transduction pathways, including MAPK and NF-κB pathways, in epithelial and endothelial 
 134 
 
cells (8).  In chapter 2, we show that MAPK and NF-κB pathways are also activated by K15 
in B lymphocytes.   
We further analyzed the signaling functions of K15 in B lymphocytes when 
expressed ectopically or in the context of viral infection.  We hypothesized that 
dysregulation of MAPK and/or NF-κB pathways by K15 may lead to changes in the cytokine 
environment.  We found that K15 induces the expression of GRO, IL-2Ra, IL-6,  IL-12 p40, 
IL-17, I-309, IGFBP-1, leptin, MCP-1, MCP-2, MCP-3, MIP-3b, MSP-1, NT-4, 
Osteoprotegrin, Oncostatin M, PDGF-BB, PIGF, TRAIL R4, sTNFRI, sTNFRII, and VEGF-D 
in B lymphocytes by at least two-fold as compared to a vector control.  Similarly, IL-6, MCP-
1, MIP3α and GRO3, IL-1α/β and IL-8 are upregulated by K15 in epithelial cells (9).   
Interleukin-6 (IL-6) is a pleiotropic cytokine, which plays a role in wound healing (28, 
52), stimulates cell proliferation (3, 39, 40, 55, 58), and prevents apoptosis (5, 16, 17) via 
its downstream effector molecules.  It is also involved in B cell maturation and 
differentiation (4, 7, 44, 75).  Upon binding to the IL-6 receptor (IL-6R), the IL-6/IL-6R 
complex interacts with the gp130 coreceptor molecule to initiate JAK-STAT signaling (50, 
76).  JAK kinases associated with the cytoplasmic tail of the gp130 coreceptor molecule are 
autophosphorylated following complex formation.   The JAK kinases in turn phosphorylate 
STAT molecules which homo- or heterodimerize and move into the nucleus to induce 
transcription of downstream effector genes (50). 
IL-6 expression is elevated in many disease states, including almost all major types 
of cancer (advanced stage breast, colorectal, lung, prostate and kidney cancers as well as 
hematological cancers such as lymphoma and multiple myeloma) (1, 2, 20-22, 25, 51, 60, 
77, 79, 84, 85, 88).  The role IL-6 plays in cancer formation is not entirely understood.  
There is no solid evidence that IL-6 alone has transformation potential.  However, some 
evidence suggests that IL-6 may play a role in initiation of B cell tumors.  Overexpression of 
IL-6 in mice results in a high incidence of plasmacytoma formation (33-35, 78), reinforcing 
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the growth stimulatory effect of IL-6 in B cells.  In fact, IL-6 has a growth stimulatory effect 
in most types of cancers and KSHV-associated malignancies (especially PEL and MCD) 
are no exception (23, 27, 42, 63).  In breast cancer and melanoma, elevated IL-6 levels are 
associated with growth inhibition at early stages, but are associated with more aggressive 
disease and poor outcomes at later stages (47-49, 62, 88).  Thus, deregulated IL-6 may 
also function in tumor maintenance and metastasis by enhancing proliferation, blocking 
apoptosis, and promoting neovascularization and metastasis.      
Although IL-6-specific antibodies did not show an effect in vitro, IL-6 neutralizing antibodies 
administered to mice injected with KSHV-positive PEL cells caused retardation or 
regression of tumor development (27).  Further emphasizing the role of IL-6 in KSHV-
associated disease, KSHV encodes an IL-6 homolog (vIL-6) that can engage the gp130 
coreceptor to initiate JAK-STAT signaling, even in the absence of the IL-6R (56, 57, 64, 
80).  vIL-6 is highly expressed in MCD where a larger fraction of cells support lytic 
replication, and to a lesser extent in PEL and KS where the majority of cells remain latent.  
In summary, these findings suggest that cells latently infected with KSHV express the IL-6 
receptor and respond normally to cellular IL-6 stimulation, but that cells undergoing lytic 
replication are less responsive to cellular IL-6 stimulation and require increased stimulation 
with the viral IL-6 homolog.  Alternatively, viral IL-6 may act in paracrine to stimulate 
proliferation of neighboring cells that do not normally express the IL-6 receptor.        
Given the importance of the IL-6 signal transduction pathway in viral pathogenesis 
and tumorigenesis, we studied the mechanisms of K15-mediated upregulation of IL-6 and 
found that K15 not only induces expression of cellular IL-6, but also of viral IL-6.  Most 
notably, activation of AP-1 transcription factors by K15 induces cellular IL-6 expression 
when K15 is expressed ectopically and in the context of viral infection.  Additionally, K15 
also induced expression of the viral IL-6 homolog when introduced into KSHV-positive PEL 
cells.   
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In chapter 3, we go on to show that JAK-STAT signaling, the downstream signaling 
pathway common to many of the cytokines induced by K15, is also deregulated in B 
lymphocytes expressing K15.  Increased levels of multiple cytokines and chemokines in 
KSHV-associated malignancies, as well as the acquisition of multiple cytokine and 
chemokine homologs by the virus, highlight the importance of cytokine signaling, and 
specifically JAK-STAT signaling, in viral tumorigenesis.  The signal transducer and activator 
of transcription 1 (STAT1) protein is hyperphosphorylated at the activating tyrosine residue 
701 in B lymphocytes expressing K15.  Activation of STAT1 by four K15 isoforms mirrors 
their ability to induce cellular IL-6.  Yet, STAT1 is typically activated by antiviral interferon 
responses leading to induction of pro-apoptotic downstream effector gene expression (11, 
26, 37, 67).  In addition, STAT1 has been proposed to have tumor suppressor activity, 
since STAT1 knockout mice incur tumors more frequently in response to carcinogens than 
mice with unimpaired STAT1 function (43).  Although activation of STAT1 by IL-6 has been 
reported (50), the terminal effects of IL-6 activation are more consistent with activation of 
the STAT3 molecule (29).  Thus, concurrent activation of STAT1 and IL-6 by K15 seemed 
perplexing and that observation instigated the experiments described in chapter 3.   
Given the characteristic role of STAT1 in antiviral responses induced by interferon, it 
is not surprising that many viruses have evolved inhibitory mechanisms—targeting STAT1 
for degradation, blocking transactivation or sequestering STAT1 outside the nucleus (12, 
32, 69, 87).  We determined that STAT1 did not bind directly to K15 in 
coimmunoprecipitation experiments.  Levels of hyperphosphorylated STAT1 were 
increased both in cytoplasmic and nuclear fractions in B lymphocytes expressing K15, 
suggesting that K15 does not stimulate STAT1 sequestration.  Furthermore, no differences 
were seen in expression of interferon-regulated genes in B cells treated with type I 
interferon as compared to control cells.  Therefore, STAT1 did not seem to be directly 
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inhibited by K15.  In the future, the role of STAT1 will need to be assessed in the context of 
viral infection, where other viral gene products could serve to regulate STAT1 activity.   
Although the downstream effects of IL-6 and STAT1 seem contradictory, like IL-6 it 
is not uncommon that STAT1 is activated in cancer.  In fact, STAT1 is upregulated in some 
of the same cancers that are associated with high IL-6 levels, including breast and multiple 
myeloma (13, 81).  Furthermore, STAT1 is upregulated in cancers associated with Epstein-
Barr virus, a gammaherpesvirus closely related to KSHV (18, 61, 82).  The latent 
membrane protein 1 (LMP1) of EBV shares functional homology with K15.  Both membrane 
proteins interact with TRAFs to signal through NF-κB and activate multiple MAPK pathways 
(10).  In addition, in vitro studies of LMP1 function have revealed that LMP1 upregulates 
STAT1 expression in B lymphomcytes by an NF-κB-dependent mechanism (68).  STAT1 
activity is increased in cells expressing LMP1 and in co-cultured cells not expressing LMP1, 
suggesting an indirect mechanism of regulation (30, 68).  Therefore, STAT1 activation may 
be a conserved function of herpesvirus membrane proteins that is important for viral 
pathogenesis or oncogenesis.  
To assess the role of K15 in a model infection, we created a KSHV∆K15 
recombinant virus in the context of a bacterial artificial chromosome.  Introduction of the 
wild type (WT) KSHV and KSHV∆K15 viruses into BJAB cells did not evidence any 
differences in cell proliferation or apoptosis, despite the fact that WT KSHV-BJAB cells 
secreted more IL-6 than KSHV∆K15 cells.  When we assessed viral load in these stable 
cell lines we noted that the differences in cell-associated viral load were small, in contrast 
to stark differences in cell-free viral load.  Cell-free viral load was five-fold greater in 
KSHV∆K15-BJAB cells as compared to WT KSHV-BJAB cells, and the difference was 
magnified upon induction of lytic replication with PMA.  Taken together these results 
suggest that K15 promotes latency by restricting lytic replication.  It may be that K15-
induced IL-6 expression and STAT1 activation promote cell survival by simultaneously 
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stimulating cell proliferation and restricting lytic replication of the virus.  Although the role of 
STAT1 was not specifically addressed in the viral load experiments discussed in chapter 3, 
we could envision a scenario where K15-mediated activation of STAT1 serves to limit viral 
replication and promote latency, while IL-6 stimulates cell proliferation.  It must be noted 
that BJAB cells are already transformed and are no longer dependent on IL-6.  Therefore, 
we did not detect differences in cell proliferation and only slight differences in cell survival.  
These studies should be repeated in primary EBV/KSHV-negative B lymphocytes following 
introduction of the two viruses to confirm this hypothesis.   
The functions we have ascribed K15 in this thesis support the notion that K15 may 
be a good candidate for drug therapy.  If K15 promotes cell proliferation via IL-6 signaling, 
then inhibition of K15 signaling could lead to impaired cell survival.  If K15 limits lytic 
replication and expression of the full complement of viral gene products, then inhibition of 
K15 signaling or targeted degradation of K15, could force the virus out of antigenic hiding.  
Used in combination with antiviral agents that block lytic replication, the virus could be 
eliminated altogether (45).  Similar strategies of purging the latent reservoir are being 
investigated for other viruses including the human immunodeficiency virus and EBV (46, 
54, 66, 86).   
 In chapter 4, we took advantage of the WT KSHV-BJAB cells in a screening assay 
to identify antiviral agents, regardless of their antiviral mechanism, with activity against 
latent KSHV infection.  KSHV-BJAB cells co-incubated with test samples are monitored for 
loss of fluorescence over time, which is a surrogate for loss of the viral episome since the 
green fluorescent protein (GFP) has been inserted into the viral genome (89).  Loss of viral 
DNA is then confirmed by real time quantitative PCR.  Toxicity is also monitored in 
uninfected BJAB cells and a naturally infected PEL cell line.  Advantages of this system 
include:  1) presence of GFP, which affords a means to screen for loss of the viral episome, 
2) KSHV-BJAB cells do not depend on the virus for survival, so selective inhibition can be 
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confirmed in the single cell line, 3) an unbiased approach does not predetermine the 
mechanism of antiviral action, and 4) cumulative toxicity can be assessed.  The major 
disadvantage of the system is the relatively long half-life of GFP which lengthens the assay, 
since the loss in fluorescence is dependent on degradation of GFP after the latent viral 
episome has been lost from the dividing cell population. 
Using the screening assay we developed, we identified two potential hits out of 81 
that we screened.  Both “hits” were plant extracts and likely contained more than one 
hundred compounds.   The extracts were composed of the detannified organic fraction of 
the root, stem, bark or leaf of understudied plants found in Papua New Guinea.  One 
extract achieved three ideal characteristics for a new antiviral agent, as it was relatively 
nontoxic to uninfected cells, toxic to naturally infected cells that depend on the virus for 
survival, and exhibited highly selective viral inhibition in KSHV-BJAB cells.  The second 
potential hit demonstrated only two of those ideals and was markedly toxic to uninfected 
cells.  Perhaps further purification will minimize the toxic effects and hone in on the 
therapeutic effects present in that extract.  Although these results still need to be narrowed 
by bioactivity assays following repeated fractionation of the extracts to pure compounds, it 
supports the utility of this type of screen in future drug discoveries.  Our study 
demonstrates the pharmaceutical potential of herbal remedies and indigenous medicinal 
plants, while a parallel study demonstrated the potential for herbal remedies, or 
“oncoweeds”, to promote KSHV replication (83). 
A deeper understanding of the contributions of each viral protein to viral 
pathogenesis and tumorigenesis may provide insight into new therapeutic strategies and 
promote targeted drug design.  The work we have done to characterize the signaling 
properties of the K15 protein of KSHV in B lymphocytes has identified K15 as a potential 
target for future therapies, as K15 activates the IL-6/JAK-STAT pathway to promote cell 
proliferation and survival while simulatenously limiting viral genome replication.  In addition 
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to these efforts, we also took an unbiased approach to identification of potential therapeutic 
compounds that target viral latency in general.  Of 82 samples screened, two exhibited 
specific viral inhibition and cytotoxicity in our in vitro assays utilizing latently infected cells.  
Although much work will be required to confirm the activity of the antiviral extracts we 
identified in chapter 4 and to elucidate their mechanism of action, we are hopeful that one 
might progress into the clinics and prove efficacious against the latent virus.  Ultimately, it is 
our hope that this thesis will contribute to the field of KSHV research and advance the 
endeavors of many researchers seeking that elusive cure for viral infection.   
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